Johnson & Johnson (JNJ) 10-Q 24 Jul 20 2020 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 28, 2020	Jul. 20, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 28, 2020
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,632,823,475
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-03
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.250% Notes Due January 2022
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes Due January 2022
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 28, 2020	Dec. 29, 2019
Current assets:
Cash and cash equivalents	$ 11,174	$ 17,305
Marketable securities	7,961	1,982
Accounts receivable, trade, less allowances for doubtful accounts and credit losses $334 (2019, $226)	14,645	14,481
Inventories (Note 2)	9,424	9,020
Prepaid expenses and other	2,588	2,392
Assets held for sale (Note 10)	100	94
Total current assets	45,892	45,274
Property, plant and equipment at cost	44,056	43,332
Less: accumulated depreciation	(26,458)	(25,674)
Property, plant and equipment, net	17,598	17,658
Intangible assets, net (Note 3)	47,413	47,643
Goodwill (Note 3)	33,890	33,639
Deferred taxes on income (Note 5)	7,805	7,819
Other assets	5,782	5,695
Total assets	158,380	157,728
Current liabilities:
Loans and notes payable	5,332	1,202
Accounts payable	6,765	8,544
Accrued liabilities	8,940	9,715
Accrued rebates, returns and promotions	11,790	10,883
Accrued compensation and employee related obligations	2,313	3,354
Accrued taxes on income (Note 5)	1,632	2,266
Total current liabilities	36,772	35,964
Long-term debt (Note 4)	25,062	26,494
Deferred taxes on income (Note 5)	5,532	5,958
Employee related obligations (Note 6)	10,411	10,663
Long-term taxes payable (Note 5)	6,591	7,444
Other liabilities	11,034	11,734
Total liabilities	95,402	98,257
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(15,533)	(15,891)
Retained earnings	113,898	110,659
Less: common stock held in treasury, at cost (487,466,000 and 487,336,000 shares)	38,507	38,417
Total shareholders’ equity	62,978	59,471
Total liabilities and shareholders' equity	$ 158,380	$ 157,728

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 29, 2019
Current assets:
Allowances for doubtful accounts	$ 334	$ 226
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000,000	4,320,000,000
Common stock, shares issued	3,119,843,000	3,119,843,000
Treasury stock, shares	487,466,000	487,336,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Income Statement [Abstract]
Sales to customers	$ 18,336	$ 20,562	$ 39,027	$ 40,583
Sales to customers percent to sales	100.00%	100.00%	100.00%	100.00%
Cost of products sold	$ 6,579	$ 6,940	$ 13,641	$ 13,555
Cost of products sold percent to sales	35.90%	33.80%	35.00%	33.40%
Gross profit	$ 11,757	$ 13,622	$ 25,386	$ 27,028
Gross profit percent to sales	64.10%	66.20%	65.00%	66.60%
Selling, marketing and administrative expenses	$ 4,993	$ 5,546	$ 10,196	$ 10,765
Selling marketing and administrative expenses percent to sales	27.20%	27.00%	26.10%	26.50%
Research and development expense	$ 2,707	$ 2,666	$ 5,287	$ 5,524
Research and development expense percent to sales	14.80%	13.00%	13.50%	13.60%
In-process research and development	$ 6	$ 0	$ 6	$ 890
In-process research and development percent to sales	0.00%	0.00%	0.00%	2.20%
Interest income	$ (19)	$ (88)	$ (86)	$ (187)
Interest income percent to sales	(0.10%)	(0.40%)	(0.20%)	(0.50%)
Interest expense, net of portion capitalized	$ 45	$ 83	$ 70	$ 185
Interest expense, net of portion capitalized percent to sales	0.30%	0.40%	0.20%	0.50%
Other (income) expense, net	$ 24	$ (1,683)	$ (655)	$ (1,705)
Other (income) expense, net percent to sales	0.10%	(8.20%)	(1.70%)	(4.20%)
Restructuring (Note 12)	$ 61	$ 57	$ 119	$ 93
Restructuring charge percent to sales	0.30%	0.20%	0.30%	0.30%
Earnings before provision for taxes on income	$ 3,940	$ 7,041	$ 10,449	$ 11,463
Earnings before provision for taxes on income percent to sales	21.50%	34.20%	26.80%	28.20%
Provision for taxes on income	$ 314	$ 1,434	$ 1,027	$ 2,107
Provision for taxes on income (Note 5)	1.70%	6.90%	2.70%	5.10%
NET EARNINGS	$ 3,626	$ 5,607	$ 9,422	$ 9,356
Net earnings percent to sales	19.80%	27.30%	24.10%	23.10%
NET EARNINGS PER SHARE
Basic (per share)	$ 1.38	$ 2.11	$ 3.58	$ 3.52
Diluted (per share)	$ 1.36	$ 2.08	$ 3.53	$ 3.47
AVG. SHARES OUTSTANDING
Basic (shares)	2,632,900	2,652,500	2,633,300	2,656,700
Diluted (shares)	2,665,500	2,691,700	2,671,000	2,697,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,000		15,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net earnings	$ 3,626	$ 5,607	$ 9,422	$ 9,356
Other comprehensive income (loss), net of tax
Foreign currency translation	556	350	(963)	92
Securities:
Unrealized holding gain (loss) arising during period	(2)	1	0	1
Reclassifications to earnings	0	0	0	0
Net change	(2)	1	0	1
Employee benefit plans:
Prior service cost amortization during period	(5)	(5)	(11)	(12)
Gain (loss) amortization during period	200	142	401	318
Net change	195	137	390	306
Derivatives & hedges:
Unrealized gain (loss) arising during period	21	86	853	(216)
Reclassifications to earnings	(60)	(26)	78	70
Net change	(39)	60	931	(146)
Other comprehensive income (loss)	710	548	358	253
Comprehensive income	4,336	6,155	9,780	9,609
Foreign Currency Translation	114	106	68	44
Securities	(1)	0	0	0
Employee Benefit Plans	55	34	111	35
Derivatives & Hedges	$ (10)	$ 16	$ 246	$ (39)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 30, 2018	$ 59,752	$ 106,216	$ (15,222)	$ 3,120	$ (34,362)
Net earnings	9,356	9,356
Cash dividends paid	(4,918)	(4,918)
Employee compensation and stock option plans	1,034	(845)			1,879
Repurchase of common stock	(4,692)				(4,692)
Other comprehensive income (loss), net of tax	253		253
Ending Balance at Jun. 30, 2019	60,785	109,809	(14,969)	3,120	(37,175)
Beginning Balance at Mar. 31, 2019	58,955	106,650	(15,517)	3,120	(35,298)
Net earnings	5,607	5,607
Cash dividends paid	(2,522)	(2,522)
Employee compensation and stock option plans	683	74			609
Repurchase of common stock	(2,486)				(2,486)
Other comprehensive income (loss), net of tax	548		548
Ending Balance at Jun. 30, 2019	60,785	109,809	(14,969)	3,120	(37,175)
Beginning Balance at Dec. 29, 2019	59,471	110,659	(15,891)	3,120	(38,417)
Net earnings	9,422	9,422
Cash dividends paid	(5,164)	(5,164)
Employee compensation and stock option plans	1,307	(1,020)			2,327
Repurchase of common stock	(2,417)				(2,417)
Other	1	1
Other comprehensive income (loss), net of tax	358		358
Ending Balance at Jun. 28, 2020	62,978	113,898	(15,533)	3,120	(38,507)
Beginning Balance at Mar. 29, 2020	61,294	112,901	(16,243)	3,120	(38,484)
Net earnings	3,626	3,626
Cash dividends paid	(2,659)	(2,659)
Employee compensation and stock option plans	712	29			683
Repurchase of common stock	(706)				(706)
Other	1	1
Other comprehensive income (loss), net of tax	710		710
Ending Balance at Jun. 28, 2020	$ 62,978	$ 113,898	$ (15,533)	$ 3,120	$ (38,507)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 1.01	$ 0.95	$ 1.96	$ 1.85

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 9,422	$ 9,356
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	3,473	3,466
Stock based compensation	589	572
Asset write-downs	33	989
Contingent consideration reversal	(983)	0
Net gain on sale of assets/businesses	(60)	(2,079)
Deferred tax provision	(428)	(694)
Credit losses and accounts receivable allowances	117	1
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(520)	(336)
Increase in inventories	(637)	(423)
Decrease in accounts payable and accrued liabilities	(2,319)	(444)
Increase in other current and non-current assets	(1,048)	(862)
Decrease in other current and non-current liabilities	(829)	(55)
NET CASH FLOWS FROM OPERATING ACTIVITIES	6,810	9,491
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(1,287)	(1,493)
Proceeds from the disposal of assets/businesses, net	87	3,018
Acquisitions, net of cash acquired	(949)	(5,346)
Purchases of investments	(8,551)	(1,517)
Sales of investments	2,417	2,132
Proceeds from credit support agreements, net	672	0
Other (primarily licenses and milestones)	(492)	1
NET CASH USED BY INVESTING ACTIVITIES	(8,103)	(3,205)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(5,164)	(4,918)
Repurchase of common stock	(2,417)	(4,692)
Proceeds from short-term debt	2,717	15
Repayment of short-term debt	(17)	(12)
Proceeds from long-term debt, net of issuance costs	1	1
Repayment of long-term debt	(11)	(1,005)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	708	463
Other	(489)	98
NET CASH USED BY FINANCING ACTIVITIES	(4,672)	(10,050)
Effect of exchange rate changes on cash and cash equivalents	(166)	33
Decrease in cash and cash equivalents	(6,131)	(3,731)
Cash and Cash equivalents, beginning of period	17,305	18,107
Cash and Cash equivalents, end of period	11,174	14,376
Acquisitions
Fair value of assets acquired	1,173	6,744
Fair value of liabilities assumed and noncontrolling interests	(224)	(1,398)
Net cash paid for acquisitions	949	$ 5,346
Auris Health
Adjustments to reconcile net earnings to cash flows from operating activities:
Contingent consideration reversal	$ (983)

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 28, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of June 28, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended June 28, 2020, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods. New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. There were no new material accounting standards issued in the fiscal second quarter of 2020 that impacted the Company. Recently Adopted Accounting Standards There were no new accounting standards adopted in the fiscal second quarter of 2020. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Inventories

Inventories	6 Months Ended
	Jun. 28, 2020
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) June 28, 2020 December 29, 2019 Raw materials and supplies $ 1,303 1,117 Goods in process 1,962 1,832 Finished goods 6,159 6,071 Total inventories (1) $ 9,424 9,020 (1) See Note 10 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jun. 28, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2019. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) June 28, 2020 December 29, 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 37,313 36,634 Less accumulated amortization 14,834 13,154 Patents and trademarks — net 22,479 23,480 Customer relationships and other intangibles — gross 22,272 22,056 Less accumulated amortization 10,072 9,462 Customer relationships and other intangibles — net* 12,200 12,594 Intangible assets with indefinite lives: Trademarks 6,927 6,922 Purchased in-process research and development (1) 5,807 4,647 Total intangible assets with indefinite lives 12,734 11,569 Total intangible assets — net $ 47,413 47,643 *The majority is comprised of customer relationships (1) In the fiscal first quarter of 2020, the Company completed the acquisition of bermekimab and certain related assets from XBiotech Inc., as well as the acquisition of all outstanding shares in Verb Surgical Inc., and recorded in-process research and development intangible assets of $0.8 billion and $0.4 billion, respectively. Goodwill as of June 28, 2020 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1 183 184 Currency translation/Other 10 45 12 67 Goodwill at June 28, 2020 $ 9,746 9,215 14,929 33,890 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion for each of the fiscal second quarters ended June 28, 2020 and June 30, 2019. The amortization expense of amortizable intangible assets included in cost of products sold was $2.2 billion for each of the fiscal six months ended June 28, 2020 and June 30, 2019. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 4,000 See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 28, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of June 28, 2020, the total amount of cash collateral held by the Company under the credit support agreements (CSA) amounted to $926 million, net. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of June 28, 2020, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $43.9 billion and $22.2 billion, respectively. As of December 29, 2019, the Company had notional amounts outstanding for forward foreign exchange contracts and cross currency interest rate swaps of $45.3 billion and $20.1 billion, respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of June 28, 2020, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $636 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2020 and 2019, net of tax: June 28, 2020 June 30, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 39 — — — — 39 — Amount of gain or (loss) recognized in AOCI — — — 39 — — — — 39 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (2) (62) 2 — — (14) (101) 36 — 2 Amount of gain or (loss) recognized in AOCI (2) (128) (10) — 22 — (50) 18 — (3) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 83 — — — 64 — Amount of gain or (loss) recognized in AOCI $ — — — 100 — — — — 82 — The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2020 and 2019, net of tax: June 28, 2020 June 30, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 79 — — — — 78 — Amount of gain or (loss) recognized in AOCI — — — 79 — — — — 78 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 7 (235) (108) — (2) (35) (136) (103) — 8 Amount of gain or (loss) recognized in AOCI 9 174 (120) — (14) (6) (346) (92) — 10 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 181 — — — — 118 — Amount of gain or (loss) recognized in AOCI $ — — — 725 — — — — 140 — The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters and fiscal six months ended in 2020 and 2019: Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended Derivatives Not Designated as Hedging Instruments June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Foreign Exchange Contracts Other (income) expense $ (24) (50) 65 (88) The following table is the effect of net investment hedges for the fiscal second quarters ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Debt $ (95) (57) Interest (income) expense — — Cross Currency interest rate swaps $ (186) (57) Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal six months ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Debt $ (48) 14 Interest (income) expense — — Cross Currency interest rate swaps $ 641 313 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 29, 2019 June 28, 2020 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 196 144 1,488 1,488 Equity Investments without readily determinable value $ 712 (28) 28 712 712 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, $39 million of the decrease in the fair value reflected in net income were the result of impairments. There were $11 million of increase in fair value reflected in net income due to changes in observable prices. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of June 28, 2020 and December 29, 2019 were as follows: June 28, 2020 December 29, 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 395 — 395 209 Interest rate contracts (2)(3) — 1,126 — 1,126 693 Total — 1,521 — 1,521 902 Liabilities: Forward foreign exchange contracts — 260 — 260 426 Interest rate contracts (3) — 251 — 251 193 Total — 511 — 511 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 38 — 38 23 Liabilities: Forward foreign exchange contracts — 47 — 47 33 Other Investments: Equity investments (4) 1,488 — — 1,488 1,148 Debt securities (5) $ — 10,047 — 10,047 4,368 Other Liabilities Contingent consideration (6) 796 796 1,715 Gross to Net Derivative Reconciliation June 28, 2020 December 29, 2019 (Dollars in Millions) Total Gross Assets $ 1,559 925 Credit Support Agreement (CSA) (1,437) (841) Total Net Asset 122 84 Total Gross Liabilities 558 652 Credit Support Agreement (CSA) (510) (586) Total Net Liabilities $ 48 66 Summarized information about changes in liabilities for contingent consideration is as follows: June 28, 2020 June 30, 2019 (Dollars in Millions) Beginning Balance $ 1,715 $ 397 Changes in estimated fair value (7) (938) 35 Additions 106 1,133 Payments (87) (3) Ending Balance $ 796 $ 1,562 (1) December 30, 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million, which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current other assets as of December 29, 2019. (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified within cash equivalents and current marketable securities. (6) Includes $793 million and $1,631 million (primarily related to Auris Health), classified as non-current other liabilities as of June 28, 2020 and December 29, 2019, respectively. Includes $3 million and $84 million classified as current liabilities as of June 28, 2020 and December 29, 2019, respectively. (7) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. During the fiscal first quarter of 2020, the Company recorded a contingent consideration reversal of $983 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The one-time reversal of the contingent consideration was recorded in Other income and expense. As of June 28, 2020, the estimated fair value of the remaining contingent consideration is $169 million. For additional details see Note 10 t o the Consolidated Financial Statements. The Company's cash, cash equivalents and current marketable securities as of June 28, 2020 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,215 — — 2,215 2,215 Non-U.S. sovereign securities (1) 655 — — 655 225 430 U.S. reverse repurchase agreements 2,372 — — 2,372 2,372 — Other reverse repurchase agreements 460 — — 460 460 Corporate debt securities (1) 1,279 — — 1,279 301 978 Money market funds 1,528 — — 1,528 1,528 Time deposits (1) 579 — — 579 579 Subtotal 9,088 — — 9,088 7,680 1,408 Unrealized Gain Unrealized Loss U.S. Gov't securities 9,786 — — 9,786 3,480 6,306 Other sovereign securities 5 — — 5 — 5 Corporate debt securities 255 1 — 256 14 242 Subtotal available for sale debt (2) $ 10,046 1 — 10,047 3,494 6,553 Total cash, cash equivalents and current marketable securities $ 19,134 1 — 19,135 11,174 7,961 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. In the fiscal year ended December 29, 2019 the carrying amount was the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities as of June 28, 2020 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 10,023 10,024 Due after one year through five years 23 23 Due after five years through ten years — — Total debt securities $ 10,046 10,047 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 28, 2020: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,332 5,388 Non-Current Debt 2.45% Notes due 2021 350 360 0.250% Notes due 2022 (1B Euro 1.1217) 1,121 1,131 2.25% Notes due 2022 998 1,029 6.73% Debentures due 2023 250 302 3.375% Notes due 2023 803 891 2.05% Notes due 2023 499 523 0.650% Notes due 2024 (750MM Euro 1.1217) 839 864 5.50% Notes due 2024 (500 MM GBP 1.2431) 618 749 2.625% Notes due 2025 748 813 2.45% Notes due 2026 1,993 2,179 2.95% Notes due 2027 997 1,111 2.90% Notes due 2028 1,494 1,681 1.150% Notes due 2028 (750MM Euro 1.1217) 835 917 6.95% Notes due 2029 297 435 4.95% Debentures due 2033 498 689 4.375% Notes due 2033 856 1,127 1.650% Notes due 2035 (1.5B Euro 1.1217) 1,667 1,974 3.55% Notes due 2036 989 1,170 5.95% Notes due 2037 992 1,531 3.625% Notes due 2037 1,487 1,791 3.40% Notes due 2038 991 1,168 5.85% Debentures due 2038 696 1,060 4.50% Debentures due 2040 539 736 4.85% Notes due 2041 297 420 4.50% Notes due 2043 495 685 3.70% Notes due 2046 1,974 2,467 3.75% Notes due 2047 991 1,255 3.50% Notes due 2048 742 923 Other 6 10 Total Non-Current Debt $ 25,062 29,991 The weighted average effective interest rate on non-current debt is 3.24%. The excess of the estimated fair value over the carrying value of debt was $3.0 billion at December 29, 2019. The Current Debt balance as of June 28, 2020 includes $2.7 billion of commercial paper which has a weighted average interest rate of 0.15% and a weighted average maturity of 3.7 months. There was no commercial paper as of December 29, 2019. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 28, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal six months of 2020 and 2019 were 9.8% an d 18.4%, respectively. In the third fiscal quarter of 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF), which became effective on January 1, 2020. More information on the provisions of TRAF, including the step-up transitional provisions, can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. During the first fiscal quarter of 2020, the final canton where the Company maintains significant operations enacted TRAF legislation and, accordingly, the Company recorded an estimated deferred tax benefit of approximately $0.3 billion for the remeasurement of existing deferred tax liabilities offset by a related $0.2 billion increase in U.S. GILTI deferred taxes. During the second fiscal quarter of 2020, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., “step-up”) for its assets. As a result, the Company recorded additional deferred tax benefits in the second fiscal quarter of 2020 to recognize this step-up. Consequently, the benefit recorded related to Swiss Tax reform in the first six months of fiscal 2020 was approximately $0.4 billion, or 3.8% benefit to the Company’s fiscal six months effective tax rate, inclusive of the impact of U.S. GILTI deferred taxes. The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. During the second fiscal quarter of 2020, the Company reversed some of its international unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions. This reserve reversal benefited the Company’s effective tax rate by approximately 1.0% for the first fiscal six months of fiscal 2020. In the first fiscal quarter of 2020, the Company reduced a contingent consideration liability related to the 2019 Auris Health acquisition that has benefited the year to date overall effective tax rate by approximately 1.0% (see Note 10 to the Consolidated Financial Statements for more details.) Additionally, the Company had less income in higher tax jurisdictions relative to lower tax jurisdictions as compared to the same period in the prior fiscal year primarily due to: • the 2019 divestiture gain related to Advanced Sterilization Products (ASP) which was primarily taxed in the U.S. • the accrual of additional legal costs, at the U.S. statutory rate, in the second fiscal quarter of 2020 (see Notes 9 and 11 to the Consolidated Financial Statements for more details) partially offset by: • the reduced income in lower tax jurisdictions due to the ongoing COVID-19 pandemic. The Company also generated additional tax benefits from stock-based compensation that were either exercised or vested during the first and second fiscal quarters. As of June 28, 2020, the Company had approximately $3.1 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2009 and is currently auditing the tax years 2010 through 2012. The Company currently expects completion of this audit and settlement of the related tax liabilities in the fiscal year 2020. As of June 28, 2020, the Company has classified unrecognized tax benefits and related interest of approximately $0.2 billion as a current liability on the “Accrued taxes on Income” line of the Consolidated Balance Sheet. This is the amount expected to be paid over the next 12 months with respect to the IRS audit. During the first fiscal quarter of 2020, the Company made a payment of approximately $0.6 billion to the U.S. Treasury with respect to the 2010-2012 tax audit in anticipation of a final settlement later in the fiscal year 2020. The completion of this tax audit may result in additional adjustments to the Company’s unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	6 Months Ended
	Jun. 28, 2020
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal second quarters and fiscal six months of 2020 and 2019 include the following components: Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Service cost $ 323 277 72 69 649 553 144 137 Interest cost 237 274 33 46 477 549 66 92 Expected return on plan assets (608) (581) (1) (1) (1,222) (1,164) (3) (3) Amortization of prior service cost/(credit) 1 1 (8) (8) 1 2 (16) (16) Recognized actuarial losses 222 146 35 33 445 290 71 65 Curtailments and settlements — 8 — — 19 7 — — Net periodic benefit cost $ 175 125 131 139 369 237 262 275 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the fiscal six months ended June 28, 2020, the Company contributed $144 million and $18 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 28, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 29, 2019 $ (8,705) — (6,891) (295) (15,891) Net change (963) — 390 931 358 June 28, 2020 $ (9,668) — (6,501) 636 (15,533) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 28, 2020
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal second quarters and fiscal six months ended June 28, 2020 and June 30, 2019: Fiscal Second Quarter Ended Fiscal Six Months Ended (Shares in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Basic net earnings per share $ 1.38 2.11 3.58 3.52 Average shares outstanding — basic 2,632.9 2,652.5 2,633.3 2,656.7 Potential shares exercisable under stock option plans 119.6 140.8 122.6 138.6 Less: shares which could be repurchased under treasury stock method (87.5) (102.3) (85.4) (99.0) Convertible debt shares 0.5 0.7 0.5 0.7 Average shares outstanding — diluted 2,665.5 2,691.7 2,671.0 2,697.0 Diluted net earnings per share $ 1.36 2.08 3.53 3.47 The diluted net earnings per share calculation for both the fiscal second quarters ended June 28, 2020 and June 30, 2019 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal second quarter ended June 28, 2020 excluded 20 million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal second quarter ended June 30, 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than their average market value.

Segments of Business and Geogra

Segments of Business and Geographic Areas	6 Months Ended
	Jun. 28, 2020
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 28, June 30, Percent June 28, June 30, Percent Change Consumer Health* Baby Care U.S. $ 96 99 (3.5) % $ 188 186 1.2 % International 260 344 (24.3) 529 651 (18.7) Worldwide 356 443 (19.7) 717 837 (14.3) Oral Care U.S. 170 155 9.7 346 306 12.9 International 227 234 (2.8) 446 450 (0.8) Worldwide 397 389 2.2 792 756 4.8 OTC U.S. 627 484 29.6 1,316 991 32.8 International 522 580 (10.1) 1,181 1,160 1.8 Worldwide 1,149 1,064 7.9 2,497 2,151 16.1 Skin Health/Beauty U.S. 536 663 (19.2) 1,195 1,251 (4.5) International 471 539 (12.5) 929 1,041 (10.7) Worldwide 1,007 1,202 (16.2) 2,124 2,292 (7.3) Women's Health U.S. 3 3 (2.9) 7 6 14.3 International 199 250 (20.4) 427 472 (9.6) Worldwide 202 253 (20.1) 434 478 (9.3) Wound Care/Other U.S. 126 132 (4.7) 245 234 4.7 International 59 61 (2.4) 111 114 (1.9) Worldwide 185 193 (4.0) 356 348 2.6 TOTAL Consumer Health U.S. 1,557 1,537 1.3 3,297 2,975 10.8 International 1,739 2,007 (13.4) 3,624 3,887 (6.8) Worldwide 3,296 3,544 (7.0) 6,921 6,862 0.9 * Previously referred to as Consumer PHARMACEUTICAL Immunology U.S. 2,362 2,379 (0.7) 4,772 4,542 5.1 International 1,161 1,087 6.8 2,389 2,175 9.8 Worldwide 3,523 3,466 1.6 7,161 6,717 6.6 REMICADE ® U.S. 593 801 (25.8) 1,218 1,575 (22.7) U.S. Exports 133 62 * 243 138 75.7 International 208 244 (14.5) 464 496 (6.4) Worldwide 935 1,107 (15.5) 1,925 2,209 (12.9) SIMPONI / SIMPONI ARIA ® U.S. 256 281 (8.7) 528 544 (2.9) International 289 282 2.6 547 543 0.8 Worldwide 546 563 (3.0) 1,075 1,087 (1.1) STELARA ® U.S. 1,138 1,058 7.5 2,355 1,940 21.4 International 558 499 11.9 1,161 1,022 13.6 Worldwide 1,697 1,558 8.9 3,516 2,963 18.7 TREMFYA ® U.S. 241 176 36.7 428 344 24.4% International 101 59 71.0 210 108 94.0 Worldwide 342 235 45.4 638 452 41.1% OTHER IMMUNOLOGY U.S. — — — — — — International 3 3 11.8 6 6 2.7 Worldwide 3 3 11.8 6 6 2.7 Infectious Diseases U.S. 416 387 7.4 852 744 14.5 International 463 475 (2.5) 946 964 (1.8) Worldwide 878 862 1.9 1,798 1,708 5.3 EDURANT ® / rilpivirine U.S. 10 12 (14.0) 22 24 (6.9) International 246 198 24.5 458 397 15.4 Worldwide 256 210 22.2 480 421 14.1 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 379 344 10.5 775 659 17.7 International 130 191 (32.0) 314 399 (21.4) Worldwide 510 535 (4.7) 1,089 1,058 2.9 OTHER INFECTIOUS DISEASES U.S. 25 31 (18.7) 54 61 (11.2) International 87 86 1.0 174 168 3.8 Worldwide 113 117 (4.2) 229 229 (0.2) Neuroscience U.S. 778 664 17.4 1,526 1,387 10.1 International 809 875 (7.6) 1,719 1,780 (3.5) Worldwide 1,587 1,538 3.2 3,245 3,167 2.5 CONCERTA ® / methylphenidate U.S. 55 15 * 107 112 (4.2) International 94 123 (23.0) 212 239 (11.0) Worldwide 149 137 8.7 320 351 (8.9) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 576 506 13.8 1,120 989 13.2 International 303 312 (2.8) 642 619 3.7 Worldwide 879 818 7.5 1,762 1,608 9.5 RISPERDAL CONSTA ® U.S. 74 81 (9.3) 150 158 (4.9) International 79 101 (21.2) 173 203 (14.9) Worldwide 153 182 (15.9) 323 361 (10.5) OTHER NEUROSCIENCE U.S. 75 62 21.5 150 128 16.8 International 331 340 (2.5) 691 719 (3.9) Worldwide 406 401 1.2 841 847 (0.7) Oncology U.S. 1,181 1,013 16.6 2,356 1,975 19.3 International 1,609 1,684 (4.4) 3,448 3,240 6.4 Worldwide 2,791 2,697 3.5 5,804 5,215 11.3 DARZALEX ® U.S. 492 369 32.9 955 721 32.3 International 409 405 1.2 883 682 29.6 Worldwide 901 774 16.3 1,838 1,403 31.0 ERLEADA ® U.S. 136 62 * 255 120 * International 33 7 * 57 10 * Worldwide 170 69 * 313 130 * IMBRUVICA ® U.S. 447 367 21.5 879 716 22.6 International 502 463 8.3 1,101 898 22.6 Worldwide 949 831 14.1 1,980 1,615 22.6 VELCADE ® U.S. — — — — — — International 98 224 (56.1) 206 487 (57.7) Worldwide 98 224 (56.1) 206 487 (57.7) ZYTIGA ® / abiraterone acetate U.S. 87 198 (55.6) 226 383 (40.9) International 480 500 (3.9) 1,032 994 3.8 Worldwide 568 698 (18.6) 1,258 1,377 (8.6) OTHER ONCOLOGY U.S. 20 16 22.9 42 34 21.4 International 87 85 2.2 169 169 (0.3) Worldwide 106 101 5.5 210 203 3.4 Pulmonary Hypertension U.S. 545 439 24.2 1,031 869 18.7 International 243 251 (3.3) 503 477 5.3 Worldwide 789 690 14.2 1,534 1,346 13.9 OPSUMIT ® U.S. 256 203 26.1 485 375 29.3 International 150 146 3.0 310 279 11.2 Worldwide 406 348 16.5 795 654 21.6 UPTRAVI ® U.S. 254 175 44.5 466 351 32.6 International 28 28 4.0 66 50 33.6 Worldwide 282 203 39.0 532 401 32.7 OTHER PULMONARY HYPERTENSION U.S. 37 61 (40.2) 81 143 (43.5) International 64 78 (17.6) 126 149 (15.1) Worldwide 101 140 (27.5) 207 292 (29.0) Cardiovascular / Metabolism / Other U.S. 837 902 (7.2) 1,643 1,849 (11.1) International 347 373 (7.0) 701 771 (9.1) Worldwide 1,184 1,275 (7.1) 2,344 2,620 (10.5) XARELTO ® U.S. 559 549 1.7 1,086 1,091 (0.5) International — — — — — — Worldwide 559 549 1.7 1,086 1,091 (0.5) INVOKANA ® / INVOKAMET ® U.S. 132 132 (0.8) 249 286 (13.0) International 47 43 9.1 105 92 14.1 Worldwide 179 177 1.6 354 379 (6.4) PROCRIT ® / EPREX ® U.S. 70 113 (38.3) 146 261 (44.1) International 66 70 (5.0) 145 148 (2.2) Worldwide 136 183 (25.6) 291 409 (28.9) OTHER U.S. 78 107 (27.7) 163 211 (22.9) International 234 260 (10.2) 451 531 (15.0) Worldwide 312 368 (15.3) 614 742 (17.3) TOTAL PHARMACEUTICAL U.S. 6,120 5,783 5.8 12,181 11,365 7.2 International 4,632 4,746 (2.4) 9,705 9,408 3.2 Worldwide 10,752 10,529 2.1 21,886 20,773 5.4 MEDICAL DEVICES Interventional Solutions U.S. 255 366 (30.5) 620 709 (12.6) International 335 385 (12.8) 697 774 (9.9) Worldwide 590 750 (21.5) 1,317 1,482 (11.2) Orthopaedics U.S. 869 1,331 (34.7) 2,119 2,649 (20.0) International 583 894 (34.8) 1,371 1,779 (22.9) Worldwide 1,451 2,224 (34.7) 3,489 4,428 (21.2) HIPS U.S. 137 216 (36.5) 343 429 (20.1) International 88 147 (39.8) 220 295 (25.4) Worldwide 226 364 (37.8) 563 725 (22.3) KNEES U.S. 108 218 (50.5) 322 441 (27.1) International 66 153 (56.8) 196 299 (34.6) Worldwide 174 372 (53.1) 517 741 (30.1) TRAUMA U.S. 354 407 (12.9) 761 824 (7.6) International 198 265 (25.2) 445 533 (16.5) Worldwide 553 672 (17.8) 1,207 1,357 (11.1) SPINE, SPORTS & OTHER U.S. 270 490 (45.0) 693 955 (27.4) International 230 328 (29.9) 510 651 (21.7) Worldwide 499 818 (39.0) 1,202 1,606 (25.1) Surgery U.S. 490 926 (47.0) 1,334 1,927 (30.8) International 1,060 1,427 (25.7) 2,317 2,821 (17.9) Worldwide 1,551 2,353 (34.1) 3,651 4,748 (23.1) ADVANCED U.S. 277 396 (30.0) 658 800 (17.7) International 498 633 (21.2) 1,065 1,209 (11.9) Worldwide 775 1,029 (24.6) 1,723 2,009 (14.2) GENERAL U.S. 213 530 (59.8) 676 1,127 (40.0) International 562 794 (29.2) 1,252 1,612 (22.4) Worldwide 775 1,325 (41.5) 1,928 2,739 (29.6) Vision U.S. 248 461 (46.1) 687 907 (24.2) International 447 701 (36.1) 1,075 1,383 (22.3) Worldwide 695 1,161 (40.1) 1,762 2,290 (23.0) CONTACT LENSES / OTHER U.S. 203 333 (39.0) 549 654 (16.1) International 352 509 (30.9) 819 1,011 (19.0) Worldwide 554 842 (34.1) 1,368 1,666 (17.9) SURGICAL U.S. 45 128 (64.6) 138 253 (45.3) International 96 191 (49.9) 256 371 (31.0) Worldwide 141 319 (55.8) 394 624 (36.8) TOTAL MEDICAL DEVICES U.S. 1,862 3,083 (39.6) 4,760 6,192 (23.1) International 2,426 3,406 (28.8) 5,460 6,756 (19.2) Worldwide 4,288 6,489 (33.9) 10,220 12,948 (21.1) WORLDWIDE U.S. 9,539 10,403 (8.3) 20,238 20,532 (1.4) International 8,797 10,159 (13.4) 18,789 20,051 (6.3) Worldwide $ 18,336 20,562 (10.8) % $ 39,027 40,583 (3.8) % *Percentage greater than 100% or not meaningful EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 28, June 30, Percent June 28, June 30, Percent Change Consumer Health (1) $ 32 406 (92.1) % $ 802 1,147 (30.1) % Pharmaceutical (2) 4,514 3,677 22.8 8,348 6,008 38.9 Medical Devices (3) (354) 3,189 * 1,671 4,686 (64.3) Segment earnings before provision for taxes 4,192 7,272 (42.4) 10,821 11,841 (8.6) Less: Expense not allocated to segments (4) 252 231 372 378 Worldwide income before tax $ 3,940 7,041 (44.0) % $ 10,449 11,463 (8.8) % *Percentage greater than 100% or not meaningful (1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (DR. CI: LABO) in the fiscal six months of 2019. Includes litigation expense of $0.6 billion and $0.2 billion in both the fiscal second quarters of 2020 and 2019, primarily talc related costs, respectively. Includes litigation expense of $0.6 billion and $0.2 billion in both the fiscal six months of 2020 and 2019, primarily talc related costs, respectively. Includes amortization expense of $0.1 billion in both the fiscal second quarters of 2020 and 2019, respectively and $0.2 billion in both the fiscal six months of 2020 and 2019, respectively. (2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset in the fiscal six months of 2019. Includes litigation expense of $0.4 billion in the fiscal six months of 2019. Includes an unrealized gain on securities of $0.5 billion and $0.2 billion in the fiscal second quarter of 2020 and 2019, respectively. Includes an unrealized gain on securities of $0.2 billion and $0.3 billion in the fiscal six months of 2020 and 2019, respectively. Additionally, the fiscal six months of 2019 includes a research and development expense of $0.3 billion for an upfront payment related to argenx. Includes amortization expense of $0.8 billion in both the fiscal second quarters of 2020 and 2019. Includes amortization expense of $1.6 billion in both the fiscal six months of 2020 and 2019. In the fiscal second quarter and early in the third quarter of 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The costs associated with these arrangements have not been significant through the fiscal second quarter of 2020. (3) Includes a contingent consideration reversal of $1.0 billion in the fiscal six months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal second quarter and six months of 2019. Includes litigation expense of $0.2 billion and $0.3 billion in the fiscal second quarter and fiscal six months of 2019, respectively. Includes a restructuring related charge of $0.1 billion and amortization expense of $0.2 billion in both the fiscal second quarters of 2020 and 2019. Includes a restructuring related charge of $0.2 billion and amortization expense of $0.5 billion in both the fiscal six months of 2020 and 2019. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 28, 2020 June 30, 2019 Percent June 28, 2020 June 30, 2019 Percent Change United States $ 9,539 10,403 (8.3) % $ 20,238 20,532 (1.4) % Europe 4,063 4,733 (14.2) 8,890 9,342 (4.8) Western Hemisphere, excluding U.S. 1,133 1,455 (22.1) 2,635 2,958 (10.9) Asia-Pacific, Africa 3,601 3,971 (9.3) 7,264 7,751 (6.3) Total $ 18,336 20,562 (10.8) % $ 39,027 40,583 (3.8) %

Business Combinations and Dives

Business Combinations and Divestitures	6 Months Ended
	Jun. 28, 2020
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES Subsequent to the quarter, on July 9, 2020, the Company sold 11.8 million shares of Idorsia LTD (“Idorsia”), or its 8.3% ownership in the company, via an accelerated bookbuild offering. The transaction resulted in gross proceeds of approximately CHF337 million ($357 million) based on a sales price of CHF 28.55/share. The Company currently has rights to at least an additional 38.7 million shares (or approximately 20% of Idorsia equity) through a convertible loan with a principal amount of CHF 445 million (due June 2027). Idorsia also has access to an approximate CHF 243 million credit facility with the Company. As of June 28, 2020, Idorsia has not made any draw-downs under the credit facility. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion. XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. Additionally, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with world-class robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the Medical Devices segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion. On April 1, 2019, the Company completed the divestiture of its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $2.0 billion. On April 1, 2019, the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion, net of cash acquired. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&D, for $3.0 billion, goodwill for $2.0 billion, marketable securities of $0.2 billion and liabilities assumed of $1.8 billion, which includes the fair value of the contingent payments mentioned above. During the fiscal second quarter of 2020, the Company finalized the purchase price allocation. There were no valuation adjustments to the assets acquired but during the fiscal first quarter of 2020, the Company recorded Other income of approximately $1.0 billion for the reversal of the contingent consideration related to the timing of certain developmental and commercial milestones, which are not expected to be met based on the Company’s current timelines. As of June 28, 2020, the fair value of the remaining contingent consideration is $0.2 billion. Further, the Company re-assessed the current value of the Auris IPR&D assets in connection with the modified development timeline and determined the fair value still exceeds the carrying value. On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion, which equates to approximately $2.1 billion, using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. The Company treated this transaction as a business combination and included it in the Consumer Health segment. During the fiscal first quarter of 2020, the Company finalized the purchase price allocation. The fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion, goodwill for $1.2 billion and liabilities assumed of $0.4 billion. The adjustments made since the date of acquisition were $0.1 billion to intangible assets, accrued liabilities, deferred taxes on income and property, plant and equipment with the offset to goodwill. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During the fiscal third quarter of 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world’s leading manufacturing services providers for health care products and technology products. The Company is

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 28, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. Due to the ongoing impacts of the COVID-19 pandemic, certain trials have been rescheduled or delayed. The Company continues to monitor its legal proceedings as the situation develops. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of June 28, 2020, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of June 28, 2020, in the United States there were approximately 800 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 8,600 with respect to the PINNACLE ® Acetabular Cup System; 15,600 with respect to pelvic meshes; 10,600 with respect to RISPERDAL ® ; 21,000 with respect to XARELTO ® ; 20,600 with respect to body powders containing talc; 300 with respect to INVOKANA ® ; and 3,700 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions which have been approved by the Québec Superior Court and the Supreme Court of British Columbia. The British Columbia order is currently the subject of the Company's appeal to broaden the scope of participants. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court entered damages awards to the three Lead Applicants. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss. The class actions in Canada are expected to be discontinued in 2020 as a result of a settlement of a group of cases. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh product s. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Along with ETHICON PHYSIOMESH ® lawsuits, there were a number of filings related to the PROCEED ® Mesh and PROCEED ® Ventral Patch products. In March 2019, the New Jersey Supreme Court entered an order consolidating all PROCEED ® and PROCEED ® Ventral Patch cases as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. The Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch products. In September 2019, plaintiffs’ attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE™ Polypropylene Hernia System cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those cases have been transferred to an MCL in Atlantic County Superior Court. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a recent verdict in October 2019 of $8 billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8 million by the trial judge. The Company will appeal the final judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson (J&J); and JPI’s collaboration partner for XARELTO ® , Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&J announced an agreement in principle to the settle the XARELTO ® cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO ® related product liability litigation. Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of pending personal injury lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, and suits have also been filed outside the United States. The majority of cases are pending in federal court, organized into a multi-district litigation in the United States District Court for the District of New Jersey. In the multi-district litigation, the parties have sought to exclude experts, through Daubert motions. In April 2020, the Court issued rulings that limit the scope of testimony, including some theories and testing methods, for certain plaintiff expert witnesses and denied plaintiffs’ attempt to limit the scope of testimony of certain of the Company’s witnesses. With this ruling made, the court has now ordered case-specific discovery to proceed. In talc cases that have previously gone to trial, the Company has obtained defense verdicts in a number of these cases but there have also been verdicts against the Company, many of which have been reversed on appeal. Most recently, in June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion, reducing the overall award to $2.1 billion. The Company believes that it has strong grounds to seek further review and/or appeal of this verdict, as well as other verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has and may settle cases. The Company has established an accrual primarily for defense costs, and reserves for potential settlement of currently pending mesothelioma cases, in connection with product liability litigation associated with body powders containing talc. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’ potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. Based on such claims as well as indemnity and insurance claims the Company has against Imerys, the Company petitioned the United States District Court for the District of Delaware to establish federal jurisdiction of the state court talc lawsuits under the Bankruptcy Code. The Company's petition was denied and the state court talc lawsuits that have been removed to federal court on such basis have been remanded. The Company previously proposed to resolve Imerys' (and the Company’s) obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, waiving the Company’s indemnification claims against Imerys, and lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys. In May 2020, Imerys and the asbestos claimants’ committee filed their Plan of Reorganization and the Disclosure Statement related thereto agreeing to put its North American operations up for auction. The Bankruptcy Court will hold a hearing to consider approval of the Disclosure Statement on August 26, 2020 and the Company is disputing any indemnification objections and the scope of coverage in the reorganization plan. Additionally, in June 2020, Cyprus Mines Corporation and its parent filed an adversary proceeding against the Company as well as Imerys seeking a declaration of indemnity under certain contractual agreements. The Company denies such indemnification is owed and is in the process of responding to the complaint In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S ® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiffs are seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, Defendants answered the complaint. Discovery is underway. In June 2019, a shareholder filed a complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson & Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption In re Johnson & Johnson Talc Stockholder Derivative Litigation , and the shareholders have until August 2020 to file a consolidated complaint or identify a previously filed complaint as the operative complaint. In July 2020, a report was delivered to the Company’s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues. The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel’s report. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants’ motion but granted leave to amend. On June 15, 2020, Plaintiffs filed an amended complaint. A lawsuit is pending in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act relating to JOHNSON’S ® Baby Powder. In that lawsuit, the plaintiffs allege that Johnson & Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. In January 2020, the Abtahi Law Group filed an action under Proposition 65 against Johnson & Johnson and Johnson & Johnson Consumer Inc. as well as a number of other alleged talcum powder manufacturers and distributors, including one California company. In that action, the plaintiff alleges contamination of talcum powder products with unsafe levels of arsenic, hexavalent chromium and lead. The plaintiff seeks civil penalties and injunctive relief. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company is cooperating with government inquiries and continues to produce documents in response. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. Lawsuits filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that Cordis’s sales of the CYPHER ™ and CYPHER SELECT ™ stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Although Johnson & Johnson has since sold Cordis, it has retained liability for this case. After the trial in January 2014, the district court dismissed the case, finding Medinol unreasonably delayed bringing its claims (the laches defense). In September 2014, the district court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol appealed the decision to the United States Court of Appeals for the Federal Circuit. In March 2017, the United States Supreme Court held that the laches defense is not available in patent cases. In April 2018, the United States Court of Appeals for the Federal Circuit remanded the case back to the district court to reconsider Medinol’s motion for a new trial. In March 2019, the district court denied Medinol’s motion for a new trial. Medinol appealed, and in June 2020, the United States Court of Appeals for the Federal Circuit affirmed the district court’s decision. In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy). MedIdea alleges infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132 (’132); 8,721,730 (’730) and 9,492,280 (’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. A claim construction hearing was held in October 2018, and a claim construction order was issued in November 2018. In December 2018, MedIdea stipulated to non-infringement of the ’132, ’730 and ’280 patents, based on the district court’s claim construction and reserving its right to appeal that construction, leaving only the ’426 patent at issue before the district court. In May 2019, DePuy filed a motion for summary judgment of non-infringement of the claims of the ’426 patent. In November 2019, judgment was entered in favor of DePuy. In December 2019, MedIdea filed a notice of appeal. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (the ’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ’284 patent), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and United States Patent Nos. 8,323,310 (the ’310 patent); 9,084,608; 9,241,759 (the ’759 patent) and 9,113,882, and seeking damages and an injunction. In June 2020, after a bench trial, the district court entered judgment in Ethicon’s favor. In July 2020, Covidien filed a notice of appeal. In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent’s RELIEVA ® Spin and RELIEVEA SpinPlus ® products infringe U.S. Patent No. 9,011,412 (the ’412 patent). Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent’s U.S. Patent No. 8,414,473. Trial is scheduled to begin in March 2021. In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® PDS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 (the ’296 patent) and 7,033,603 (the ’603 patent) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the United States Patent and Trademark Office (USPTO), seeking Inter Partes Review (IPR) of both asserted patents. In June 2020,the USPTO denied institution of the ’296 patent IPR and granted institution of the ’603 patent IPR. UT dismissed the ’603 patent from the suit and no longer accuses PDS ® Plus Antibacterial Sutures or STRATAFIX ® PDS ® Plus Antibacterial Sutures of infringement. The previously scheduled district court trial has been postponed. In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (“Intuitive”) filed a patent infringement suit against Auris Health, Inc. (“Auris”) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (’200 patent); 6,491,701 (’701 patent); 6,522,906 (’906 patent); 6,800,056 (’056 patent); 8,142,447 (’447 patent); 8,620,473 (’473 patent); 8,801,601 (’601 patent); and 9,452,276 (’276 patent) based on Auris’ Monarch™ Platform. Auris filed IPR Petitions with the USPTO regarding the ’200, ’056, ’601 ’701, ’447, ’276 and ’906 patents. Intuitive subsequently dropped the ’200 and ’701 patents from the suit. In December 2019, the USPTO instituted review of the ’601 patent and denied review of the ’056 patent. In February and March 2020, the USPTO instituted review of the ’200, ’447, ’701 and ’906 patents a

Restructuring

Restructuring	6 Months Ended
	Jun. 28, 2020
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the global supply chain restructuring strategic collaborations see Note 10 to the Consolidated Financial Statements. In the fiscal second quarter of 2020, the Company recorded a pre-tax charge of $115 million, which is included on the following lines of the Consolidated Statement of Earnings, $61 million in restructuring, $22 million in cost of products sold and $32 million in other (income) expense. In the first fiscal six months of 2020, the Company recorded a pre-tax charge of $233 million, which is included on the following lines of the Consolidated Statement of Earnings, $119 million in restructuring, $37 million in cost of products sold and $77 million in other (income) expense.Total project costs of approximately $1.1 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion, over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated restructuring expenses through the first fiscal six months of 2020: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 Current year activity: Charges — 27 206 233 Cash payments (12) — (197) (209) Settled non cash — (27) (17) (3) (44) Reserve balance, June 28, 2020 (1) $ 152 — 8 160 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	6 Months Ended
	Mar. 29, 2020	Jun. 28, 2020
Accounting Policies [Abstract]
Use of Estimates		Use of Estimates The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of June 28, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other long-lived assets. While there was not a material impact to the Company’s consolidated financial statements as of and for the quarter ended June 28, 2020, the Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.
New Accounting Standards Recently Adopted		New Accounting Standards The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019. There were no new material accounting standards issued in the fiscal second quarter of 2020 that impacted the Company. Recently Adopted Accounting Standards There were no new accounting standards adopted in the fiscal second quarter of 2020.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	6 Months Ended
	Jun. 28, 2020
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 28, 2020
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) June 28, 2020 December 29, 2019 Raw materials and supplies $ 1,303 1,117 Goods in process 1,962 1,832 Finished goods 6,159 6,071 Total inventories (1) $ 9,424 9,020 (1) See Note 10 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 28, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) June 28, 2020 December 29, 2019 Intangible assets with definite lives: Patents and trademarks — gross $ 37,313 36,634 Less accumulated amortization 14,834 13,154 Patents and trademarks — net 22,479 23,480 Customer relationships and other intangibles — gross 22,272 22,056 Less accumulated amortization 10,072 9,462 Customer relationships and other intangibles — net* 12,200 12,594 Intangible assets with indefinite lives: Trademarks 6,927 6,922 Purchased in-process research and development (1) 5,807 4,647 Total intangible assets with indefinite lives 12,734 11,569 Total intangible assets — net $ 47,413 47,643 *The majority is comprised of customer relationships
Goodwill	Goodwill as of June 28, 2020 was allocated by segment of business as follows: (Dollars in Millions) Consumer Health Pharmaceutical Medical Devices Total Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 Goodwill, related to acquisitions — 1 183 184 Currency translation/Other 10 45 12 67 Goodwill at June 28, 2020 $ 9,746 9,215 14,929 33,890
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 4,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 28, 2020
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended in 2020 and 2019, net of tax: June 28, 2020 June 30, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 39 — — — — 39 — Amount of gain or (loss) recognized in AOCI — — — 39 — — — — 39 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (2) (62) 2 — — (14) (101) 36 — 2 Amount of gain or (loss) recognized in AOCI (2) (128) (10) — 22 — (50) 18 — (3) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 83 — — — 64 — Amount of gain or (loss) recognized in AOCI $ — — — 100 — — — — 82 — The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended in 2020 and 2019, net of tax: June 28, 2020 June 30, 2019 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 79 — — — — 78 — Amount of gain or (loss) recognized in AOCI — — — 79 — — — — 78 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income 7 (235) (108) — (2) (35) (136) (103) — 8 Amount of gain or (loss) recognized in AOCI 9 174 (120) — (14) (6) (346) (92) — 10 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 181 — — — — 118 — Amount of gain or (loss) recognized in AOCI $ — — — 725 — — — — 140 — The following table is the effect of net investment hedges for the fiscal second quarters ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Debt $ (95) (57) Interest (income) expense — — Cross Currency interest rate swaps $ (186) (57) Interest (income) expense — — The following table is the effect of net investment hedges for the fiscal six months ended in 2020 and 2019 Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Debt $ (48) 14 Interest (income) expense — — Cross Currency interest rate swaps $ 641 313 Interest (income) expense — —
Schedule of Derivatives Recorded in Consolidated Balance Sheet
Schedule of Effect of Derivatives not Designated as Hedging Instruments	Gain/(Loss) Gain/(Loss) (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Second Quarter Ended Fiscal Six Months Ended Derivatives Not Designated as Hedging Instruments June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Foreign Exchange Contracts Other (income) expense $ (24) (50) 65 (88)
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 29, 2019 June 28, 2020 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,148 196 144 1,488 1,488 Equity Investments without readily determinable value $ 712 (28) 28 712 712 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of June 28, 2020 and December 29, 2019 were as follows: June 28, 2020 December 29, 2019 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 395 — 395 209 Interest rate contracts (2)(3) — 1,126 — 1,126 693 Total — 1,521 — 1,521 902 Liabilities: Forward foreign exchange contracts — 260 — 260 426 Interest rate contracts (3) — 251 — 251 193 Total — 511 — 511 619 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 38 — 38 23 Liabilities: Forward foreign exchange contracts — 47 — 47 33 Other Investments: Equity investments (4) 1,488 — — 1,488 1,148 Debt securities (5) $ — 10,047 — 10,047 4,368 Other Liabilities Contingent consideration (6) 796 796 1,715 Gross to Net Derivative Reconciliation June 28, 2020 December 29, 2019 (Dollars in Millions) Total Gross Assets $ 1,559 925 Credit Support Agreement (CSA) (1,437) (841) Total Net Asset 122 84 Total Gross Liabilities 558 652 Credit Support Agreement (CSA) (510) (586) Total Net Liabilities $ 48 66 Summarized information about changes in liabilities for contingent consideration is as follows: June 28, 2020 June 30, 2019 (Dollars in Millions) Beginning Balance $ 1,715 $ 397 Changes in estimated fair value (7) (938) 35 Additions 106 1,133 Payments (87) (3) Ending Balance $ 796 $ 1,562 (1) December 30, 2019 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,148 million, which are classified as Level 1 and contingent consideration of $1,715 million, classified as Level 3. (2) Includes $1 million of non-current other assets as of December 29, 2019. (3) Includes cross currency interest rate swaps and interest rate swaps. (4) Classified as non-current other assets. (5) Classified within cash equivalents and current marketable securities. (6) Includes $793 million and $1,631 million (primarily related to Auris Health), classified as non-current other liabilities as of June 28, 2020 and December 29, 2019, respectively. Includes $3 million and $84 million classified as current liabilities as of June 28, 2020 and December 29, 2019, respectively. (7) Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. During the fiscal first quarter of 2020, the Company recorded a contingent consideration reversal of $983 million related to the timing of certain developmental milestones associated with the Auris Health acquisition. The one-time reversal of the contingent consideration was recorded in Other income and expense. As of June 28, 2020, the estimated fair value of the remaining contingent consideration is $169 million. For additional details see Note 10 t o the Consolidated Financial Statements.
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of June 28, 2020 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,215 — — 2,215 2,215 Non-U.S. sovereign securities (1) 655 — — 655 225 430 U.S. reverse repurchase agreements 2,372 — — 2,372 2,372 — Other reverse repurchase agreements 460 — — 460 460 Corporate debt securities (1) 1,279 — — 1,279 301 978 Money market funds 1,528 — — 1,528 1,528 Time deposits (1) 579 — — 579 579 Subtotal 9,088 — — 9,088 7,680 1,408 Unrealized Gain Unrealized Loss U.S. Gov't securities 9,786 — — 9,786 3,480 6,306 Other sovereign securities 5 — — 5 — 5 Corporate debt securities 255 1 — 256 14 242 Subtotal available for sale debt (2) $ 10,046 1 — 10,047 3,494 6,553 Total cash, cash equivalents and current marketable securities $ 19,134 1 — 19,135 11,174 7,961 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of June 28, 2020 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 10,023 10,024 Due after one year through five years 23 23 Due after five years through ten years — — Total debt securities $ 10,046 10,047
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 28, 2020: (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 5,332 5,388 Non-Current Debt 2.45% Notes due 2021 350 360 0.250% Notes due 2022 (1B Euro 1.1217) 1,121 1,131 2.25% Notes due 2022 998 1,029 6.73% Debentures due 2023 250 302 3.375% Notes due 2023 803 891 2.05% Notes due 2023 499 523 0.650% Notes due 2024 (750MM Euro 1.1217) 839 864 5.50% Notes due 2024 (500 MM GBP 1.2431) 618 749 2.625% Notes due 2025 748 813 2.45% Notes due 2026 1,993 2,179 2.95% Notes due 2027 997 1,111 2.90% Notes due 2028 1,494 1,681 1.150% Notes due 2028 (750MM Euro 1.1217) 835 917 6.95% Notes due 2029 297 435 4.95% Debentures due 2033 498 689 4.375% Notes due 2033 856 1,127 1.650% Notes due 2035 (1.5B Euro 1.1217) 1,667 1,974 3.55% Notes due 2036 989 1,170 5.95% Notes due 2037 992 1,531 3.625% Notes due 2037 1,487 1,791 3.40% Notes due 2038 991 1,168 5.85% Debentures due 2038 696 1,060 4.50% Debentures due 2040 539 736 4.85% Notes due 2041 297 420 4.50% Notes due 2043 495 685 3.70% Notes due 2046 1,974 2,467 3.75% Notes due 2047 991 1,255 3.50% Notes due 2048 742 923 Other 6 10 Total Non-Current Debt $ 25,062 29,991

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	6 Months Ended
	Jun. 28, 2020
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal second quarters and fiscal six months of 2020 and 2019 include the following components: Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Service cost $ 323 277 72 69 649 553 144 137 Interest cost 237 274 33 46 477 549 66 92 Expected return on plan assets (608) (581) (1) (1) (1,222) (1,164) (3) (3) Amortization of prior service cost/(credit) 1 1 (8) (8) 1 2 (16) (16) Recognized actuarial losses 222 146 35 33 445 290 71 65 Curtailments and settlements — 8 — — 19 7 — — Net periodic benefit cost $ 175 125 131 139 369 237 262 275

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 28, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 29, 2019 $ (8,705) — (6,891) (295) (15,891) Net change (963) — 390 931 358 June 28, 2020 $ (9,668) — (6,501) 636 (15,533)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 28, 2020
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal second quarters and fiscal six months ended June 28, 2020 and June 30, 2019: Fiscal Second Quarter Ended Fiscal Six Months Ended (Shares in Millions) June 28, 2020 June 30, 2019 June 28, 2020 June 30, 2019 Basic net earnings per share $ 1.38 2.11 3.58 3.52 Average shares outstanding — basic 2,632.9 2,652.5 2,633.3 2,656.7 Potential shares exercisable under stock option plans 119.6 140.8 122.6 138.6 Less: shares which could be repurchased under treasury stock method (87.5) (102.3) (85.4) (99.0) Convertible debt shares 0.5 0.7 0.5 0.7 Average shares outstanding — diluted 2,665.5 2,691.7 2,671.0 2,697.0 Diluted net earnings per share $ 1.36 2.08 3.53 3.47

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	6 Months Ended
	Jun. 28, 2020
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 28, June 30, Percent June 28, June 30, Percent Change Consumer Health* Baby Care U.S. $ 96 99 (3.5) % $ 188 186 1.2 % International 260 344 (24.3) 529 651 (18.7) Worldwide 356 443 (19.7) 717 837 (14.3) Oral Care U.S. 170 155 9.7 346 306 12.9 International 227 234 (2.8) 446 450 (0.8) Worldwide 397 389 2.2 792 756 4.8 OTC U.S. 627 484 29.6 1,316 991 32.8 International 522 580 (10.1) 1,181 1,160 1.8 Worldwide 1,149 1,064 7.9 2,497 2,151 16.1 Skin Health/Beauty U.S. 536 663 (19.2) 1,195 1,251 (4.5) International 471 539 (12.5) 929 1,041 (10.7) Worldwide 1,007 1,202 (16.2) 2,124 2,292 (7.3) Women's Health U.S. 3 3 (2.9) 7 6 14.3 International 199 250 (20.4) 427 472 (9.6) Worldwide 202 253 (20.1) 434 478 (9.3) Wound Care/Other U.S. 126 132 (4.7) 245 234 4.7 International 59 61 (2.4) 111 114 (1.9) Worldwide 185 193 (4.0) 356 348 2.6 TOTAL Consumer Health U.S. 1,557 1,537 1.3 3,297 2,975 10.8 International 1,739 2,007 (13.4) 3,624 3,887 (6.8) Worldwide 3,296 3,544 (7.0) 6,921 6,862 0.9 * Previously referred to as Consumer PHARMACEUTICAL Immunology U.S. 2,362 2,379 (0.7) 4,772 4,542 5.1 International 1,161 1,087 6.8 2,389 2,175 9.8 Worldwide 3,523 3,466 1.6 7,161 6,717 6.6 REMICADE ® U.S. 593 801 (25.8) 1,218 1,575 (22.7) U.S. Exports 133 62 * 243 138 75.7 International 208 244 (14.5) 464 496 (6.4) Worldwide 935 1,107 (15.5) 1,925 2,209 (12.9) SIMPONI / SIMPONI ARIA ® U.S. 256 281 (8.7) 528 544 (2.9) International 289 282 2.6 547 543 0.8 Worldwide 546 563 (3.0) 1,075 1,087 (1.1) STELARA ® U.S. 1,138 1,058 7.5 2,355 1,940 21.4 International 558 499 11.9 1,161 1,022 13.6 Worldwide 1,697 1,558 8.9 3,516 2,963 18.7 TREMFYA ® U.S. 241 176 36.7 428 344 24.4% International 101 59 71.0 210 108 94.0 Worldwide 342 235 45.4 638 452 41.1% OTHER IMMUNOLOGY U.S. — — — — — — International 3 3 11.8 6 6 2.7 Worldwide 3 3 11.8 6 6 2.7 Infectious Diseases U.S. 416 387 7.4 852 744 14.5 International 463 475 (2.5) 946 964 (1.8) Worldwide 878 862 1.9 1,798 1,708 5.3 EDURANT ® / rilpivirine U.S. 10 12 (14.0) 22 24 (6.9) International 246 198 24.5 458 397 15.4 Worldwide 256 210 22.2 480 421 14.1 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 379 344 10.5 775 659 17.7 International 130 191 (32.0) 314 399 (21.4) Worldwide 510 535 (4.7) 1,089 1,058 2.9 OTHER INFECTIOUS DISEASES U.S. 25 31 (18.7) 54 61 (11.2) International 87 86 1.0 174 168 3.8 Worldwide 113 117 (4.2) 229 229 (0.2) Neuroscience U.S. 778 664 17.4 1,526 1,387 10.1 International 809 875 (7.6) 1,719 1,780 (3.5) Worldwide 1,587 1,538 3.2 3,245 3,167 2.5 CONCERTA ® / methylphenidate U.S. 55 15 * 107 112 (4.2) International 94 123 (23.0) 212 239 (11.0) Worldwide 149 137 8.7 320 351 (8.9) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 576 506 13.8 1,120 989 13.2 International 303 312 (2.8) 642 619 3.7 Worldwide 879 818 7.5 1,762 1,608 9.5 RISPERDAL CONSTA ® U.S. 74 81 (9.3) 150 158 (4.9) International 79 101 (21.2) 173 203 (14.9) Worldwide 153 182 (15.9) 323 361 (10.5) OTHER NEUROSCIENCE U.S. 75 62 21.5 150 128 16.8 International 331 340 (2.5) 691 719 (3.9) Worldwide 406 401 1.2 841 847 (0.7) Oncology U.S. 1,181 1,013 16.6 2,356 1,975 19.3 International 1,609 1,684 (4.4) 3,448 3,240 6.4 Worldwide 2,791 2,697 3.5 5,804 5,215 11.3 DARZALEX ® U.S. 492 369 32.9 955 721 32.3 International 409 405 1.2 883 682 29.6 Worldwide 901 774 16.3 1,838 1,403 31.0 ERLEADA ® U.S. 136 62 * 255 120 * International 33 7 * 57 10 * Worldwide 170 69 * 313 130 * IMBRUVICA ® U.S. 447 367 21.5 879 716 22.6 International 502 463 8.3 1,101 898 22.6 Worldwide 949 831 14.1 1,980 1,615 22.6 VELCADE ® U.S. — — — — — — International 98 224 (56.1) 206 487 (57.7) Worldwide 98 224 (56.1) 206 487 (57.7) ZYTIGA ® / abiraterone acetate U.S. 87 198 (55.6) 226 383 (40.9) International 480 500 (3.9) 1,032 994 3.8 Worldwide 568 698 (18.6) 1,258 1,377 (8.6) OTHER ONCOLOGY U.S. 20 16 22.9 42 34 21.4 International 87 85 2.2 169 169 (0.3) Worldwide 106 101 5.5 210 203 3.4 Pulmonary Hypertension U.S. 545 439 24.2 1,031 869 18.7 International 243 251 (3.3) 503 477 5.3 Worldwide 789 690 14.2 1,534 1,346 13.9 OPSUMIT ® U.S. 256 203 26.1 485 375 29.3 International 150 146 3.0 310 279 11.2 Worldwide 406 348 16.5 795 654 21.6 UPTRAVI ® U.S. 254 175 44.5 466 351 32.6 International 28 28 4.0 66 50 33.6 Worldwide 282 203 39.0 532 401 32.7 OTHER PULMONARY HYPERTENSION U.S. 37 61 (40.2) 81 143 (43.5) International 64 78 (17.6) 126 149 (15.1) Worldwide 101 140 (27.5) 207 292 (29.0) Cardiovascular / Metabolism / Other U.S. 837 902 (7.2) 1,643 1,849 (11.1) International 347 373 (7.0) 701 771 (9.1) Worldwide 1,184 1,275 (7.1) 2,344 2,620 (10.5) XARELTO ® U.S. 559 549 1.7 1,086 1,091 (0.5) International — — — — — — Worldwide 559 549 1.7 1,086 1,091 (0.5) INVOKANA ® / INVOKAMET ® U.S. 132 132 (0.8) 249 286 (13.0) International 47 43 9.1 105 92 14.1 Worldwide 179 177 1.6 354 379 (6.4) PROCRIT ® / EPREX ® U.S. 70 113 (38.3) 146 261 (44.1) International 66 70 (5.0) 145 148 (2.2) Worldwide 136 183 (25.6) 291 409 (28.9) OTHER U.S. 78 107 (27.7) 163 211 (22.9) International 234 260 (10.2) 451 531 (15.0) Worldwide 312 368 (15.3) 614 742 (17.3) TOTAL PHARMACEUTICAL U.S. 6,120 5,783 5.8 12,181 11,365 7.2 International 4,632 4,746 (2.4) 9,705 9,408 3.2 Worldwide 10,752 10,529 2.1 21,886 20,773 5.4 MEDICAL DEVICES Interventional Solutions U.S. 255 366 (30.5) 620 709 (12.6) International 335 385 (12.8) 697 774 (9.9) Worldwide 590 750 (21.5) 1,317 1,482 (11.2) Orthopaedics U.S. 869 1,331 (34.7) 2,119 2,649 (20.0) International 583 894 (34.8) 1,371 1,779 (22.9) Worldwide 1,451 2,224 (34.7) 3,489 4,428 (21.2) HIPS U.S. 137 216 (36.5) 343 429 (20.1) International 88 147 (39.8) 220 295 (25.4) Worldwide 226 364 (37.8) 563 725 (22.3) KNEES U.S. 108 218 (50.5) 322 441 (27.1) International 66 153 (56.8) 196 299 (34.6) Worldwide 174 372 (53.1) 517 741 (30.1) TRAUMA U.S. 354 407 (12.9) 761 824 (7.6) International 198 265 (25.2) 445 533 (16.5) Worldwide 553 672 (17.8) 1,207 1,357 (11.1) SPINE, SPORTS & OTHER U.S. 270 490 (45.0) 693 955 (27.4) International 230 328 (29.9) 510 651 (21.7) Worldwide 499 818 (39.0) 1,202 1,606 (25.1) Surgery U.S. 490 926 (47.0) 1,334 1,927 (30.8) International 1,060 1,427 (25.7) 2,317 2,821 (17.9) Worldwide 1,551 2,353 (34.1) 3,651 4,748 (23.1) ADVANCED U.S. 277 396 (30.0) 658 800 (17.7) International 498 633 (21.2) 1,065 1,209 (11.9) Worldwide 775 1,029 (24.6) 1,723 2,009 (14.2) GENERAL U.S. 213 530 (59.8) 676 1,127 (40.0) International 562 794 (29.2) 1,252 1,612 (22.4) Worldwide 775 1,325 (41.5) 1,928 2,739 (29.6) Vision U.S. 248 461 (46.1) 687 907 (24.2) International 447 701 (36.1) 1,075 1,383 (22.3) Worldwide 695 1,161 (40.1) 1,762 2,290 (23.0) CONTACT LENSES / OTHER U.S. 203 333 (39.0) 549 654 (16.1) International 352 509 (30.9) 819 1,011 (19.0) Worldwide 554 842 (34.1) 1,368 1,666 (17.9) SURGICAL U.S. 45 128 (64.6) 138 253 (45.3) International 96 191 (49.9) 256 371 (31.0) Worldwide 141 319 (55.8) 394 624 (36.8) TOTAL MEDICAL DEVICES U.S. 1,862 3,083 (39.6) 4,760 6,192 (23.1) International 2,426 3,406 (28.8) 5,460 6,756 (19.2) Worldwide 4,288 6,489 (33.9) 10,220 12,948 (21.1) WORLDWIDE U.S. 9,539 10,403 (8.3) 20,238 20,532 (1.4) International 8,797 10,159 (13.4) 18,789 20,051 (6.3) Worldwide $ 18,336 20,562 (10.8) % $ 39,027 40,583 (3.8) % *Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business	EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 28, June 30, Percent June 28, June 30, Percent Change Consumer Health (1) $ 32 406 (92.1) % $ 802 1,147 (30.1) % Pharmaceutical (2) 4,514 3,677 22.8 8,348 6,008 38.9 Medical Devices (3) (354) 3,189 * 1,671 4,686 (64.3) Segment earnings before provision for taxes 4,192 7,272 (42.4) 10,821 11,841 (8.6) Less: Expense not allocated to segments (4) 252 231 372 378 Worldwide income before tax $ 3,940 7,041 (44.0) % $ 10,449 11,463 (8.8) % *Percentage greater than 100% or not meaningful (1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (DR. CI: LABO) in the fiscal six months of 2019. Includes litigation expense of $0.6 billion and $0.2 billion in both the fiscal second quarters of 2020 and 2019, primarily talc related costs, respectively. Includes litigation expense of $0.6 billion and $0.2 billion in both the fiscal six months of 2020 and 2019, primarily talc related costs, respectively. Includes amortization expense of $0.1 billion in both the fiscal second quarters of 2020 and 2019, respectively and $0.2 billion in both the fiscal six months of 2020 and 2019, respectively. (2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset in the fiscal six months of 2019. Includes litigation expense of $0.4 billion in the fiscal six months of 2019. Includes an unrealized gain on securities of $0.5 billion and $0.2 billion in the fiscal second quarter of 2020 and 2019, respectively. Includes an unrealized gain on securities of $0.2 billion and $0.3 billion in the fiscal six months of 2020 and 2019, respectively. Additionally, the fiscal six months of 2019 includes a research and development expense of $0.3 billion for an upfront payment related to argenx. Includes amortization expense of $0.8 billion in both the fiscal second quarters of 2020 and 2019. Includes amortization expense of $1.6 billion in both the fiscal six months of 2020 and 2019. In the fiscal second quarter and early in the third quarter of 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. The costs associated with these arrangements have not been significant through the fiscal second quarter of 2020. (3) Includes a contingent consideration reversal of $1.0 billion in the fiscal six months of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal second quarter and six months of 2019. Includes litigation expense of $0.2 billion and $0.3 billion in the fiscal second quarter and fiscal six months of 2019, respectively. Includes a restructuring related charge of $0.1 billion and
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal Second Quarter Ended Fiscal Six Months Ended (Dollars in Millions) June 28, 2020 June 30, 2019 Percent June 28, 2020 June 30, 2019 Percent Change United States $ 9,539 10,403 (8.3) % $ 20,238 20,532 (1.4) % Europe 4,063 4,733 (14.2) 8,890 9,342 (4.8) Western Hemisphere, excluding U.S. 1,133 1,455 (22.1) 2,635 2,958 (10.9) Asia-Pacific, Africa 3,601 3,971 (9.3) 7,264 7,751 (6.3) Total $ 18,336 20,562 (10.8) % $ 39,027 40,583 (3.8) %

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 28, 2020
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated restructuring expenses through the first fiscal six months of 2020: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 29, 2019 $ 164 — 16 180 Current year activity: Charges — 27 206 233 Cash payments (12) — (197) (209) Settled non cash — (27) (17) (3) (44) Reserve balance, June 28, 2020 (1) $ 152 — 8 160 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 29, 2019
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 1,303	$ 1,117
Goods in process	1,962	1,832
Finished goods	6,159	6,071
Total inventories	$ 9,424	$ 9,020

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 29, 2019
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 12,734	$ 11,569
Total intangible assets - net	47,413	47,643
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	6,927	6,922
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	5,807	4,647
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	37,313	36,634
Less accumulated amortization	14,834	13,154
Finite-Lived Intangible Assets, Net	22,479	23,480
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	22,272	22,056
Less accumulated amortization	10,072	9,462
Finite-Lived Intangible Assets, Net	$ 12,200	$ 12,594

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	6 Months Ended
	Jun. 28, 2020USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 33,639
Goodwill, related to acquisitions	184
Currency translation/Other	67
Goodwill End of Period	33,890
Consumer Health*
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,736
Goodwill, related to acquisitions	0
Currency translation/Other	10
Goodwill End of Period	9,746
PHARMACEUTICAL
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,169
Goodwill, related to acquisitions	1
Currency translation/Other	45
Goodwill End of Period	9,215
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	14,734
Goodwill, related to acquisitions	183
Currency translation/Other	12
Goodwill End of Period	$ 14,929

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019	Mar. 29, 2020	Dec. 29, 2019
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 12,734		$ 12,734			$ 11,569
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	1,100	$ 1,100	$ 2,200	$ 2,200
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life			12 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life			21 years
Purchased In-Process Research And Development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 5,807		$ 5,807			$ 4,647
Purchased In-Process Research And Development | bermekimab
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)					$ 800
Purchased In-Process Research And Development | Verb Surgical Inc.
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)					$ 400

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details) $ in Millions	Jun. 28, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 4,500
2021	4,300
2022	4,100
2023	4,100
2024	$ 4,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019	Dec. 29, 2019
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	$ 1,488		$ 1,488		$ 1,148
Accumulated other comprehensive income on derivatives, after tax	636		$ 636
Reclassification of foreign exchange contracts into earnings, period			next 12 months
Maximum length of time for hedge exposure			18 months
Unrealized gains on equity investments	$ (2)	$ 1	$ 0	$ 1
Weighted average interest rate on non-current debt	3.24%		3.24%
Excess of the estimated fair value over the carrying value of debt					3,000
Current Debt	$ 5,332		$ 5,332		1,202
Reversal of contingent consideration			938	(35)
Commercial Paper
Derivative [Line Items]
Current Debt	$ 2,700		$ 2,700
Weighted average interest rate	0.15%		0.15%
Term			3 months 21 days
Forward foreign exchange contracts
Derivative [Line Items]
Collateral Already Posted, Aggregate Fair Value	$ 926		$ 926
Derivative, Notional Amount	43,900		43,900		45,300
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Notional Amount	22,200		22,200		20,100
Interest Rate Contract
Derivative [Line Items]
Derivative Asset, Noncurrent					1
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Equity, Fair Value Adjustment, Impairment Loss			(39)
Equity, Fair Value Adjustment, Change In Observable Price			11
Equity Securities without Readily Determinable Fair Value, Amount	712		712		$ 712
Changes in Fair Value Reflected in Net Income			(28)
Equity Investments with readily determinable value | Equity Securities
Derivative [Line Items]
Changes in Fair Value Reflected in Net Income			196
Other (income) expense
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Fair Value Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	39	39	79	78
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	39	39	79	78
Fair Value Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(2)	(14)	7	(35)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(2)	0	9	(6)
Cash Flow Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Cost of Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(62)	(101)	(235)	(136)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(128)	(50)	174	(346)
Cash Flow Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0		0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	2	36	(108)	(103)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(10)	18	(120)	(92)
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	83	64	181	118
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	100	82	725	140
Cash Flow Hedging [Member] | Other (income) expense | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	2	(2)	8
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	22	(3)	(14)	10
Cash Flow Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 796		$ 796		$ 1,715
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income	60	$ 26	(78)	$ (70)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	21	86	853	(216)
Other (income) expense
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Forward foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Collateral Already Posted, Aggregate Fair Value	926		926
Derivative, Notional Amount	43,900		43,900		45,300
Cross currency interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	22,200		22,200		$ 20,100
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	39	39	79	78
Unrealized gain (loss) arising during period	39	39	79	78
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(2)	0	9	(6)
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(2)	(14)	7	(35)
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(128)	(50)	174	(346)
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(62)	(101)	(235)	(136)
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(10)	18	(120)	(92)
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	2	36	(108)	(103)
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	22	(3)	(14)	10
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	2	(2)	8
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0		0	0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0	0	0
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	100	82	725	140
Summary of designated derivatives
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	$ 83	$ 64	$ 181	$ 118

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 29, 2019
Fair Value Disclosures [Abstract]
Business Combination, Contingent Consideration, Liability	$ 796	$ 1,715
Carrying Amount of the Hedged Liability	$ 48	$ 66

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 796		$ 796		$ 1,715
Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ (24)	$ (50)	$ 65	$ (88)

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019	Dec. 29, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 796		$ 796		$ 1,715
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	(95)	$ (57)	(48)	$ 14
Sale of Subsidiary Gain (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0	0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	$ (186)	$ (57)	$ 641	$ 313

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 28, 2020	Dec. 29, 2019
Other Investment Not Readily Marketable [Line Items]
Business Combination, Contingent Consideration, Liability	$ 796	$ 1,715
Equity Investment [Roll Forward]
Non Current Other Assets	5,782	$ 5,695
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	1,148
Changes in Fair Value Reflected in Net Income	196
Sales/ Purchases/Other	144
Carrying value, end of period	1,488
Non Current Other Assets	1,488
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	712
Changes in Fair Value Reflected in Net Income	(28)
Sales/ Purchases/Other	28
Carrying value, end of period	712
Non Current Other Assets	$ 712

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Dec. 29, 2019	Apr. 01, 2019
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 1,521
Derivatives designated as hedging instruments : Liabilities	511
Available-for-sale Securities, Equity Securities	1,488		$ 1,148
Available-for-sale Securities	10,047		4,368
Total Gross Assets	1,559		925
Credit Support Agreement (CSA)	(1,437)		(841)
Total Net Asset	122		84
Total Gross Liabilities	558		652
Credit Support Agreement (CSA)	(510)		(586)
Total Net Liabilities	48		66
Beginning Balance	796	$ 1,562
Changes in estimated fair value (7)	(938)	35
Additions	106	1,133
Payments	(87)	(3)
Ending Balance	1,715	397
Contingent consideration	796		1,715
Contingent consideration reversal	(983)	$ 0
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	1,488		1,148
Available-for-sale Securities	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,521		902
Derivatives designated as hedging instruments : Liabilities	511		619
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	10,047
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Contingent consideration	796		1,715
Interest Rate Contract
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,126
Derivatives designated as hedging instruments : Liabilities	251
Derivative Assets, Noncurrent			1
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,126		693
Derivatives designated as hedging instruments : Liabilities	251		193
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivative, Notional Amount	43,900		45,300
Derivatives designated as hedging instruments : Assets	395
Derivatives designated as hedging instruments : Liabilities	260
Derivatives not designated as hedging instruments : Assets	38
Derivatives not designated as hedging instruments : Liabilities	47
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	395		209
Derivatives designated as hedging instruments : Liabilities	260		426
Derivatives not designated as hedging instruments : Assets	38		23
Derivatives not designated as hedging instruments : Liabilities	47		33
Forward foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Cross currency interest rate swaps
Financial assets and liabilities at fair value
Derivative, Notional Amount	22,200		20,100
Auris Health
Financial assets and liabilities at fair value
Contingent consideration	200			$ 2,350
Contingent consideration reversal	(983)
Other Noncurrent Liabilities
Financial assets and liabilities at fair value
Contingent consideration	169
Other Noncurrent Liabilities | Auris Health
Financial assets and liabilities at fair value
Contingent consideration	793		1,631
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration	$ 3		$ 84

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 29, 2019
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 10,047	$ 4,368
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	11,174	17,305
Marketable securities	7,961	$ 1,982
Total cash, cash equivalents and current marketable securities, Carrying Amount	19,134
Total cash, cash equivalents and current marketable securities, Unrecognized Gain	1
Total cash, cash equivalents and current marketable securities, Unrecognized Loss	0
Total cash, cash equivalents and current marketable securities, Estimated Fair Value	19,135
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	9,088
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	9,088
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	7,680
Marketable securities	1,408
Held-to-maturity Securities | Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,215
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,215
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,215
Held-to-maturity Securities | Non-U.S. sovereign securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	655
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	655
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	225
Marketable securities	430
Held-to-maturity Securities | U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,372
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	2,372
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,372
Marketable securities	0
Held-to-maturity Securities | Other reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	460
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	460
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	460
Held-to-maturity Securities | Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,279
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,279
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	301
Marketable securities	978
Held-to-maturity Securities | Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,528
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	1,528
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,528
Held-to-maturity Securities | Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	579
Held-to-maturity Securities, Unrecognized Gain	0
Held-to-maturity Securities, Unrecognized Loss	0
Held-to-maturity Securities - Estimated Fair Value	579
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	579
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	10,046
Available-for-sale Securities, Unrecognized Gain	1
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	10,047
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,494
Marketable securities	6,553
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	255
Available-for-sale Securities, Unrecognized Gain	1
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	256
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	14
Marketable securities	242
Available-for-sale Securities | US Treasury and Government [Member]
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	9,786
Available-for-sale Securities, Unrecognized Gain	0
Available-for-sale Securities, Unrecognized Loss	0
Available-for-sale Securities - Estimated Fair Value	9,786
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,480
Marketable securities	$ 6,306

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Jun. 28, 2020USD ($)
Cost Basis
Due within one year	$ 10,023
Due after one year through five years	23
Due after five years through ten years	0
Total debt securities	10,046
Fair Value
Due within one year	10,024
Due after one year through five years	23
Due after five years through ten years	0
Total debt securities	$ 10,047

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Jun. 28, 2020	Dec. 29, 2019
Financial Liabilities
Current Debt	$ 5,332	$ 1,202
Non-Current Debt
Non-Current Debt	25,062	$ 26,494
Carrying Amount
Financial Liabilities
Current Debt	5,332
Non-Current Debt
Non-Current Debt	25,062
Estimated Fair Value
Financial Liabilities
Current Debt	5,388
Non-Current Debt
Non-Current Debt	$ 29,991
3.55% Notes due 2021 [Member]
Non-Current Debt
Stated interest rate (as a percent)	3.55%
2.45% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 350
2.45% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 360
0.250% Notes due 2022 (1B Euro 1.1217)
Non-Current Debt
Stated interest rate (as a percent)	0.25%
0.250% Notes due 2022 (1B Euro 1.1217) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,121
0.250% Notes due 2022 (1B Euro 1.1217) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,131
2.25% Notes due 2022
Non-Current Debt
Stated interest rate (as a percent)	2.25%
2.25% Notes due 2022 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 998
2.25% Notes due 2022 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,029
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 302
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 803
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 891
2.05% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 499
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 523
0.650% Notes due 2024 (750MM Euro 1.1217)
Non-Current Debt
Stated interest rate (as a percent)	0.65%
0.650% Notes due 2024 (750MM Euro 1.1217) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 839
0.650% Notes due 2024 (750MM Euro 1.1217) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 864
5.50% Notes due 2024 (500 MM GBP 1.2431)
Non-Current Debt
Stated interest rate (as a percent)	5.50%
5.50% Notes due 2024 (500 MM GBP 1.2431) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 618
5.50% Notes due 2024 (500 MM GBP 1.2431) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 749
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 748
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 813
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,993
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,179
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,111
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,494
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,681
1.150% Notes due 2028 (750MM Euro 1.1217)
Non-Current Debt
Stated interest rate (as a percent)	1.15%
1.150% Notes due 2028 (750MM Euro 1.1217) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 835
1.150% Notes due 2028 (750MM Euro 1.1217) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 917
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 435
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 689
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 856
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,127
1.650% Notes due 2035 (1.5B Euro 1.1217)
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.650% Notes due 2035 (1.5B Euro 1.1217) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,667
1.650% Notes due 2035 (1.5B Euro 1.1217) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,974
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 989
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,170
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,531
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,487
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,791
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,168
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 696
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,060
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 539
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 736
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 420
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 685
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,974
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,467
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,255
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 742
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	923
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	6
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 10

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Mar. 29, 2020	Jun. 28, 2020	Jun. 30, 2019
Income Tax (Textuals)
Worldwide effective income tax rate (as a percent)			9.80%	18.40%
Deferred tax benefit related to TRAF		$ 0.3	$ 0.4
Deferred tax liability related to TRAF		$ 0.2
Deferred tax benefit related to TRAF, percent			3.80%
Impact to effective tax rate, percent			1.00%
Net impact to tax rate due to change in contingent consideration liability	1.00%
Unrecognized tax benefits	$ 3.1		$ 3.1
Accrued Taxes On Income [Member]
Income Tax (Textuals)
Unrecognized tax benefits	0.2		$ 0.2
Internal Revenue Service (IRS) [Member]
Income Tax (Textuals)
Payment on unrecognized tax benefit liability	$ 0.6

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 323	$ 277	$ 649	$ 553
Interest cost	237	274	477	549
Expected return on plan assets	(608)	(581)	(1,222)	(1,164)
Amortization of prior service cost/(credit)	1	1	1	2
Recognized actuarial losses	222	146	445	290
Curtailments and settlements	0	8	19	7
Net periodic benefit cost	175	125	369	237
Other Benefit Plans
Components of net periodic benefit cost
Service cost	72	69	144	137
Interest cost	33	46	66	92
Expected return on plan assets	(1)	(1)	(3)	(3)
Amortization of prior service cost/(credit)	(8)	(8)	(16)	(16)
Recognized actuarial losses	35	33	71	65
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 131	$ 139	$ 262	$ 275

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	6 Months Ended
	Jun. 28, 2020USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 144
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 18

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 61,294	$ 58,955	$ 59,471	$ 59,752
Net change	710	548	358	253
Ending Balance	62,978	60,785	62,978	60,785
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(8,705)
Net change			(963)
Ending Balance	(9,668)		(9,668)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			0
Net change			0
Ending Balance	0		0
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(6,891)
Net change			390
Ending Balance	(6,501)		(6,501)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(295)
Net change			931
Ending Balance	636		636
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(16,243)	(15,517)	(15,891)	(15,222)
Net change	710	548	358	253
Ending Balance	$ (15,533)	$ (14,969)	$ (15,533)	$ (14,969)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.38	$ 2.11	$ 3.58	$ 3.52
Average shares outstanding — basic	2,632,900	2,652,500	2,633,300	2,656,700
Potential shares exercisable under stock option plans	119,600	140,800	122,600	138,600
Less: shares which could be repurchased under treasury stock method	(87,500)	(102,300)	(85,400)	(99,000)
Convertible debt shares	500	700	500	700
Average shares outstanding — diluted	2,665,500	2,691,700	2,671,000	2,697,000
Diluted net earnings per share	$ 1.36	$ 2.08	$ 3.53	$ 3.47
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,000		15,000

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Sales by segment of business
Sales to customers	$ 18,336	$ 20,562	$ 39,027	$ 40,583
Percent Change (as a percent)	(10.80%)		(3.80%)
U.S.
Sales by segment of business
Sales to customers	$ 9,539	10,403	$ 20,238	20,532
Percent Change (as a percent)	(8.30%)		(1.40%)
International
Sales by segment of business
Sales to customers	$ 8,797	10,159	$ 18,789	20,051
Percent Change (as a percent)	(13.40%)		(6.30%)
Consumer Health*
Sales by segment of business
Sales to customers	$ 3,296	3,544	$ 6,921	$ 6,862
Percent Change (as a percent)	(7.00%)			0.90%
Consumer Health* | U.S.
Sales by segment of business
Sales to customers	$ 1,557	1,537	3,297	$ 2,975
Percent Change (as a percent)	1.30%			10.80%
Consumer Health* | International
Sales by segment of business
Sales to customers	$ 1,739	2,007	3,624	$ 3,887
Percent Change (as a percent)	(13.40%)			(6.80%)
Consumer Health* | Baby Care
Sales by segment of business
Sales to customers	$ 356	443	717	$ 837
Percent Change (as a percent)	(19.70%)			(14.30%)
Consumer Health* | Baby Care | U.S.
Sales by segment of business
Sales to customers	$ 96	99	$ 188	$ 186
Percent Change (as a percent)	(3.50%)		1.20%
Consumer Health* | Baby Care | International
Sales by segment of business
Sales to customers	$ 260	344	$ 529	$ 651
Percent Change (as a percent)	(24.30%)			(18.70%)
Consumer Health* | Oral Care
Sales by segment of business
Sales to customers	$ 397	389	792	$ 756
Percent Change (as a percent)	2.20%			4.80%
Consumer Health* | Oral Care | U.S.
Sales by segment of business
Sales to customers	$ 170	155	346	$ 306
Percent Change (as a percent)	9.70%			12.90%
Consumer Health* | Oral Care | International
Sales by segment of business
Sales to customers	$ 227	234	446	$ 450
Percent Change (as a percent)	(2.80%)			(0.80%)
Consumer Health* | OTC
Sales by segment of business
Sales to customers	$ 1,149	1,064	2,497	$ 2,151
Percent Change (as a percent)	7.90%			16.10%
Consumer Health* | OTC | U.S.
Sales by segment of business
Sales to customers	$ 627	484	1,316	$ 991
Percent Change (as a percent)	29.60%			32.80%
Consumer Health* | OTC | International
Sales by segment of business
Sales to customers	$ 522	580	1,181	$ 1,160
Percent Change (as a percent)	(10.10%)			1.80%
Consumer Health* | Skin Health/Beauty
Sales by segment of business
Sales to customers	$ 1,007	1,202	2,124	$ 2,292
Percent Change (as a percent)	(16.20%)			(7.30%)
Consumer Health* | Skin Health/Beauty | U.S.
Sales by segment of business
Sales to customers	$ 536	663	1,195	$ 1,251
Percent Change (as a percent)	(19.20%)			(4.50%)
Consumer Health* | Skin Health/Beauty | International
Sales by segment of business
Sales to customers	$ 471	539	929	$ 1,041
Percent Change (as a percent)	(12.50%)			(10.70%)
Consumer Health* | Women's Health
Sales by segment of business
Sales to customers	$ 202	253	434	$ 478
Percent Change (as a percent)	(20.10%)			(9.30%)
Consumer Health* | Women's Health | U.S.
Sales by segment of business
Sales to customers	$ 3	3	7	$ 6
Percent Change (as a percent)	(2.90%)			14.30%
Consumer Health* | Women's Health | International
Sales by segment of business
Sales to customers	$ 199	250	427	$ 472
Percent Change (as a percent)	(20.40%)			(9.60%)
Consumer Health* | Wound Care/Other
Sales by segment of business
Sales to customers	$ 185	193	356	$ 348
Percent Change (as a percent)	(4.00%)			2.60%
Consumer Health* | Wound Care/Other | U.S.
Sales by segment of business
Sales to customers	$ 126	132	245	$ 234
Percent Change (as a percent)	(4.70%)			4.70%
Consumer Health* | Wound Care/Other | International
Sales by segment of business
Sales to customers	$ 59	61	111	$ 114
Percent Change (as a percent)	(2.40%)			(1.90%)
PHARMACEUTICAL
Sales by segment of business
Sales to customers	$ 10,752	10,529	$ 21,886	$ 20,773
Percent Change (as a percent)	2.10%		5.40%
PHARMACEUTICAL | U.S.
Sales by segment of business
Sales to customers	$ 6,120	5,783	$ 12,181	11,365
Percent Change (as a percent)	5.80%		7.20%
PHARMACEUTICAL | International
Sales by segment of business
Sales to customers	$ 4,632	4,746	$ 9,705	9,408
Percent Change (as a percent)	(2.40%)		3.20%
PHARMACEUTICAL | Immunology
Sales by segment of business
Sales to customers	$ 3,523	3,466	$ 7,161	6,717
Percent Change (as a percent)	1.60%		6.60%
PHARMACEUTICAL | Immunology | U.S.
Sales by segment of business
Sales to customers	$ 2,362	2,379	$ 4,772	4,542
Percent Change (as a percent)	(0.70%)		5.10%
PHARMACEUTICAL | Immunology | International
Sales by segment of business
Sales to customers	$ 1,161	1,087	$ 2,389	2,175
Percent Change (as a percent)	6.80%		9.80%
PHARMACEUTICAL | Immunology | REMICADE®
Sales by segment of business
Sales to customers	$ 935	1,107	$ 1,925	2,209
Percent Change (as a percent)	(15.50%)		(12.90%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S.
Sales by segment of business
Sales to customers	$ 593	801	$ 1,218	1,575
Percent Change (as a percent)	(25.80%)		(22.70%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports
Sales by segment of business
Sales to customers	$ 133	62	$ 243	138
Percent Change (as a percent)			75.70%
PHARMACEUTICAL | Immunology | REMICADE® | International
Sales by segment of business
Sales to customers	$ 208	244	$ 464	496
Percent Change (as a percent)	(14.50%)		(6.40%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA®
Sales by segment of business
Sales to customers	$ 546	563	$ 1,075	1,087
Percent Change (as a percent)	(3.00%)		(1.10%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S.
Sales by segment of business
Sales to customers	$ 256	281	$ 528	544
Percent Change (as a percent)	(8.70%)		(2.90%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International
Sales by segment of business
Sales to customers	$ 289	282	$ 547	543
Percent Change (as a percent)	2.60%		0.80%
PHARMACEUTICAL | Immunology | STELARA®
Sales by segment of business
Sales to customers	$ 1,697	1,558	$ 3,516	2,963
Percent Change (as a percent)	8.90%		18.70%
PHARMACEUTICAL | Immunology | STELARA® | U.S.
Sales by segment of business
Sales to customers	$ 1,138	1,058	$ 2,355	1,940
Percent Change (as a percent)	7.50%		21.40%
PHARMACEUTICAL | Immunology | STELARA® | International
Sales by segment of business
Sales to customers	$ 558	499	$ 1,161	1,022
Percent Change (as a percent)	11.90%		13.60%
PHARMACEUTICAL | Immunology | TREMFYA®
Sales by segment of business
Sales to customers	$ 342	235	$ 638	452
Percent Change (as a percent)	45.40%		41.10%
PHARMACEUTICAL | Immunology | TREMFYA® | U.S.
Sales by segment of business
Sales to customers	$ 241	176	$ 428	344
Percent Change (as a percent)	36.70%		24.40%
PHARMACEUTICAL | Immunology | TREMFYA® | International
Sales by segment of business
Sales to customers	$ 101	59	$ 210	108
Percent Change (as a percent)	71.00%		94.00%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 3	3	$ 6	6
Percent Change (as a percent)	11.80%		2.70%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales to customers	$ 3	3	$ 6	6
Percent Change (as a percent)	11.80%		2.70%
PHARMACEUTICAL | Infectious Diseases
Sales by segment of business
Sales to customers	$ 878	862	$ 1,798	1,708
Percent Change (as a percent)	1.90%		5.30%
PHARMACEUTICAL | Infectious Diseases | U.S.
Sales by segment of business
Sales to customers	$ 416	387	$ 852	744
Percent Change (as a percent)	7.40%		14.50%
PHARMACEUTICAL | Infectious Diseases | International
Sales by segment of business
Sales to customers	$ 463	475	$ 946	964
Percent Change (as a percent)	(2.50%)		(1.80%)
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine
Sales by segment of business
Sales to customers	$ 256	210	$ 480	421
Percent Change (as a percent)	22.20%		14.10%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S.
Sales by segment of business
Sales to customers	$ 10	12	$ 22	24
Percent Change (as a percent)	(14.00%)		(6.90%)
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International
Sales by segment of business
Sales to customers	$ 246	198	$ 458	397
Percent Change (as a percent)	24.50%		15.40%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
Sales by segment of business
Sales to customers	$ 510	535	$ 1,089	1,058
Percent Change (as a percent)	(4.70%)		2.90%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S.
Sales by segment of business
Sales to customers	$ 379	344	$ 775	659
Percent Change (as a percent)	10.50%		17.70%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International
Sales by segment of business
Sales to customers	$ 130	191	$ 314	399
Percent Change (as a percent)	(32.00%)		(21.40%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES
Sales by segment of business
Sales to customers	$ 113	117	$ 229	229
Percent Change (as a percent)	(4.20%)		(0.20%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.
Sales by segment of business
Sales to customers	$ 25	31	$ 54	61
Percent Change (as a percent)	(18.70%)		(11.20%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International
Sales by segment of business
Sales to customers	$ 87	86	$ 174	168
Percent Change (as a percent)	1.00%		3.80%
PHARMACEUTICAL | Neuroscience
Sales by segment of business
Sales to customers	$ 1,587	1,538	$ 3,245	3,167
Percent Change (as a percent)	3.20%		2.50%
PHARMACEUTICAL | Neuroscience | U.S.
Sales by segment of business
Sales to customers	$ 778	664	$ 1,526	1,387
Percent Change (as a percent)	17.40%		10.10%
PHARMACEUTICAL | Neuroscience | International
Sales by segment of business
Sales to customers	$ 809	875	$ 1,719	1,780
Percent Change (as a percent)	(7.60%)		(3.50%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate
Sales by segment of business
Sales to customers	$ 149	137	$ 320	351
Percent Change (as a percent)	8.70%		(8.90%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S.
Sales by segment of business
Sales to customers	$ 55	15	$ 107	112
Percent Change (as a percent)			(4.20%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International
Sales by segment of business
Sales to customers	$ 94	123	$ 212	239
Percent Change (as a percent)	(23.00%)		(11.00%)
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
Sales by segment of business
Sales to customers	$ 879	818	$ 1,762	1,608
Percent Change (as a percent)	7.50%		9.50%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S.
Sales by segment of business
Sales to customers	$ 576	506	$ 1,120	989
Percent Change (as a percent)	13.80%		13.20%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International
Sales by segment of business
Sales to customers	$ 303	312	$ 642	619
Percent Change (as a percent)	(2.80%)		3.70%
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA®
Sales by segment of business
Sales to customers	$ 153	182	$ 323	361
Percent Change (as a percent)	(15.90%)		(10.50%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S.
Sales by segment of business
Sales to customers	$ 74	81	$ 150	158
Percent Change (as a percent)	(9.30%)		(4.90%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International
Sales by segment of business
Sales to customers	$ 79	101	$ 173	203
Percent Change (as a percent)	(21.20%)		(14.90%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 406	401	$ 841	847
Percent Change (as a percent)	1.20%		(0.70%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales to customers	$ 75	62	$ 150	128
Percent Change (as a percent)	21.50%		16.80%
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales to customers	$ 331	340	$ 691	719
Percent Change (as a percent)	(2.50%)		(3.90%)
PHARMACEUTICAL | Oncology
Sales by segment of business
Sales to customers	$ 2,791	2,697	$ 5,804	5,215
Percent Change (as a percent)	3.50%		11.30%
PHARMACEUTICAL | Oncology | U.S.
Sales by segment of business
Sales to customers	$ 1,181	1,013	$ 2,356	1,975
Percent Change (as a percent)	16.60%		19.30%
PHARMACEUTICAL | Oncology | International
Sales by segment of business
Sales to customers	$ 1,609	1,684	$ 3,448	3,240
Percent Change (as a percent)	(4.40%)		6.40%
PHARMACEUTICAL | Oncology | DARZALEX®
Sales by segment of business
Sales to customers	$ 901	774	$ 1,838	1,403
Percent Change (as a percent)	16.30%		31.00%
PHARMACEUTICAL | Oncology | DARZALEX® | U.S.
Sales by segment of business
Sales to customers	$ 492	369	$ 955	721
Percent Change (as a percent)	32.90%		32.30%
PHARMACEUTICAL | Oncology | DARZALEX® | International
Sales by segment of business
Sales to customers	$ 409	405	$ 883	682
Percent Change (as a percent)	1.20%		29.60%
PHARMACEUTICAL | Oncology | ERLEADA [Member]
Sales by segment of business
Sales to customers	$ 170	69	$ 313	130
PHARMACEUTICAL | Oncology | ERLEADA [Member] | U.S.
Sales by segment of business
Sales to customers	136	62	255	120
PHARMACEUTICAL | Oncology | ERLEADA [Member] | International
Sales by segment of business
Sales to customers	33	7	57	10
PHARMACEUTICAL | Oncology | IMBRUVICA®
Sales by segment of business
Sales to customers	$ 949	831	$ 1,980	1,615
Percent Change (as a percent)	14.10%		22.60%
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S.
Sales by segment of business
Sales to customers	$ 447	367	$ 879	716
Percent Change (as a percent)	21.50%		22.60%
PHARMACEUTICAL | Oncology | IMBRUVICA® | International
Sales by segment of business
Sales to customers	$ 502	463	$ 1,101	898
Percent Change (as a percent)	8.30%		22.60%
PHARMACEUTICAL | Oncology | VELCADE®
Sales by segment of business
Sales to customers	$ 98	224	$ 206	487
Percent Change (as a percent)	(56.10%)		(57.70%)
PHARMACEUTICAL | Oncology | VELCADE® | U.S.
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Oncology | VELCADE® | International
Sales by segment of business
Sales to customers	$ 98	224	$ 206	487
Percent Change (as a percent)	(56.10%)		(57.70%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate
Sales by segment of business
Sales to customers	$ 568	698	$ 1,258	1,377
Percent Change (as a percent)	(18.60%)		(8.60%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S.
Sales by segment of business
Sales to customers	$ 87	198	$ 226	383
Percent Change (as a percent)	(55.60%)		(40.90%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International
Sales by segment of business
Sales to customers	$ 480	500	$ 1,032	994
Percent Change (as a percent)	(3.90%)		3.80%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY
Sales by segment of business
Sales to customers	$ 106	101	$ 210	203
Percent Change (as a percent)	5.50%		3.40%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 20	16	$ 42	34
Percent Change (as a percent)	22.90%		21.40%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International
Sales by segment of business
Sales to customers	$ 87	85	$ 169	169
Percent Change (as a percent)	2.20%		(0.30%)
PHARMACEUTICAL | Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 789	690	$ 1,534	1,346
Percent Change (as a percent)	14.20%		13.90%
PHARMACEUTICAL | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales to customers	$ 545	439	$ 1,031	869
Percent Change (as a percent)	24.20%		18.70%
PHARMACEUTICAL | Pulmonary Hypertension | International
Sales by segment of business
Sales to customers	$ 243	251	$ 503	477
Percent Change (as a percent)	(3.30%)		5.30%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT®
Sales by segment of business
Sales to customers	$ 406	348	$ 795	654
Percent Change (as a percent)	16.50%		21.60%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S.
Sales by segment of business
Sales to customers	$ 256	203	$ 485	375
Percent Change (as a percent)	26.10%		29.30%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International
Sales by segment of business
Sales to customers	$ 150	146	$ 310	279
Percent Change (as a percent)	3.00%		11.20%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI®
Sales by segment of business
Sales to customers	$ 282	203	$ 532	401
Percent Change (as a percent)	39.00%		32.70%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S.
Sales by segment of business
Sales to customers	$ 254	175	$ 466	351
Percent Change (as a percent)	44.50%		32.60%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International
Sales by segment of business
Sales to customers	$ 28	28	$ 66	50
Percent Change (as a percent)	4.00%		33.60%
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION
Sales by segment of business
Sales to customers	$ 101	140	$ 207	292
Percent Change (as a percent)	(27.50%)		(29.00%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | U.S.
Sales by segment of business
Sales to customers	$ 37	61	$ 81	143
Percent Change (as a percent)	(40.20%)		(43.50%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | International
Sales by segment of business
Sales to customers	$ 64	78	$ 126	149
Percent Change (as a percent)	(17.60%)		(15.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 1,184	1,275	$ 2,344	2,620
Percent Change (as a percent)	(7.10%)		(10.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales to customers	$ 837	902	$ 1,643	1,849
Percent Change (as a percent)	(7.20%)		(11.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales to customers	$ 347	373	$ 701	771
Percent Change (as a percent)	(7.00%)		(9.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO®
Sales by segment of business
Sales to customers	$ 559	549	$ 1,086	1,091
Percent Change (as a percent)	1.70%		(0.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S.
Sales by segment of business
Sales to customers	$ 559	549	$ 1,086	1,091
Percent Change (as a percent)	1.70%		(0.50%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET®
Sales by segment of business
Sales to customers	$ 179	177	$ 354	379
Percent Change (as a percent)	1.60%		(6.40%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S.
Sales by segment of business
Sales to customers	$ 132	132	$ 249	286
Percent Change (as a percent)	(0.80%)		(13.00%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International
Sales by segment of business
Sales to customers	$ 47	43	$ 105	92
Percent Change (as a percent)	9.10%		14.10%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX®
Sales by segment of business
Sales to customers	$ 136	183	$ 291	409
Percent Change (as a percent)	(25.60%)		(28.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S.
Sales by segment of business
Sales to customers	$ 70	113	$ 146	261
Percent Change (as a percent)	(38.30%)		(44.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International
Sales by segment of business
Sales to customers	$ 66	70	$ 145	148
Percent Change (as a percent)	(5.00%)		(2.20%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION
Sales by segment of business
Sales to customers	$ 312	368	$ 614	$ 742
Percent Change (as a percent)	(15.30%)			(17.30%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | U.S.
Sales by segment of business
Sales to customers	$ 78	107	$ 163	$ 211
Percent Change (as a percent)	(27.70%)		(22.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | International
Sales by segment of business
Sales to customers	$ 234	260	$ 451	531
Percent Change (as a percent)	(10.20%)		(15.00%)
MEDICAL DEVICES
Sales by segment of business
Sales to customers	$ 4,288	6,489	$ 10,220	12,948
Percent Change (as a percent)	(33.90%)		(21.10%)
MEDICAL DEVICES | U.S.
Sales by segment of business
Sales to customers	$ 1,862	3,083	$ 4,760	6,192
Percent Change (as a percent)	(39.60%)		(23.10%)
MEDICAL DEVICES | International
Sales by segment of business
Sales to customers	$ 2,426	3,406	$ 5,460	6,756
Percent Change (as a percent)	(28.80%)		(19.20%)
MEDICAL DEVICES | Interventional Solutions
Sales by segment of business
Sales to customers	$ 590	750	$ 1,317	1,482
Percent Change (as a percent)	(21.50%)		(11.20%)
MEDICAL DEVICES | Interventional Solutions | U.S.
Sales by segment of business
Sales to customers	$ 255	366	$ 620	709
Percent Change (as a percent)	(30.50%)		(12.60%)
MEDICAL DEVICES | Interventional Solutions | International
Sales by segment of business
Sales to customers	$ 335	385	$ 697	774
Percent Change (as a percent)	(12.80%)		(9.90%)
MEDICAL DEVICES | Orthopaedics
Sales by segment of business
Sales to customers	$ 1,451	2,224	$ 3,489	4,428
Percent Change (as a percent)	(34.70%)		(21.20%)
MEDICAL DEVICES | Orthopaedics | U.S.
Sales by segment of business
Sales to customers	$ 869	1,331	$ 2,119	2,649
Percent Change (as a percent)	(34.70%)		(20.00%)
MEDICAL DEVICES | Orthopaedics | International
Sales by segment of business
Sales to customers	$ 583	894	$ 1,371	1,779
Percent Change (as a percent)	(34.80%)		(22.90%)
MEDICAL DEVICES | Orthopaedics | HIPS
Sales by segment of business
Sales to customers	$ 226	364	$ 563	725
Percent Change (as a percent)	(37.80%)		(22.30%)
MEDICAL DEVICES | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales to customers	$ 137	216	$ 343	429
Percent Change (as a percent)	(36.50%)		(20.10%)
MEDICAL DEVICES | Orthopaedics | HIPS | International
Sales by segment of business
Sales to customers	$ 88	147	$ 220	295
Percent Change (as a percent)	(39.80%)		(25.40%)
MEDICAL DEVICES | Orthopaedics | KNEES
Sales by segment of business
Sales to customers	$ 174	372	$ 517	741
Percent Change (as a percent)	(53.10%)		(30.10%)
MEDICAL DEVICES | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales to customers	$ 108	218	$ 322	441
Percent Change (as a percent)	(50.50%)		(27.10%)
MEDICAL DEVICES | Orthopaedics | KNEES | International
Sales by segment of business
Sales to customers	$ 66	153	$ 196	299
Percent Change (as a percent)	(56.80%)		(34.60%)
MEDICAL DEVICES | Orthopaedics | TRAUMA
Sales by segment of business
Sales to customers	$ 553	672	$ 1,207	1,357
Percent Change (as a percent)	(17.80%)		(11.10%)
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales to customers	$ 354	407	$ 761	824
Percent Change (as a percent)	(12.90%)		(7.60%)
MEDICAL DEVICES | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales to customers	$ 198	265	$ 445	533
Percent Change (as a percent)	(25.20%)		(16.50%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER
Sales by segment of business
Sales to customers	$ 499	818	$ 1,202	1,606
Percent Change (as a percent)	(39.00%)		(25.10%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | U.S.
Sales by segment of business
Sales to customers	$ 270	490	$ 693	955
Percent Change (as a percent)	(45.00%)		(27.40%)
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | International
Sales by segment of business
Sales to customers	$ 230	328	$ 510	651
Percent Change (as a percent)	(29.90%)		(21.70%)
MEDICAL DEVICES | Surgery
Sales by segment of business
Sales to customers	$ 1,551	2,353	$ 3,651	4,748
Percent Change (as a percent)	(34.10%)		(23.10%)
MEDICAL DEVICES | Surgery | U.S.
Sales by segment of business
Sales to customers	$ 490	926	$ 1,334	1,927
Percent Change (as a percent)	(47.00%)		(30.80%)
MEDICAL DEVICES | Surgery | International
Sales by segment of business
Sales to customers	$ 1,060	1,427	$ 2,317	2,821
Percent Change (as a percent)	(25.70%)		(17.90%)
MEDICAL DEVICES | Surgery | ADVANCED
Sales by segment of business
Sales to customers	$ 775	1,029	$ 1,723	2,009
Percent Change (as a percent)	(24.60%)		(14.20%)
MEDICAL DEVICES | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales to customers	$ 277	396	$ 658	800
Percent Change (as a percent)	(30.00%)		(17.70%)
MEDICAL DEVICES | Surgery | ADVANCED | International
Sales by segment of business
Sales to customers	$ 498	633	$ 1,065	1,209
Percent Change (as a percent)	(21.20%)		(11.90%)
MEDICAL DEVICES | Surgery | GENERAL
Sales by segment of business
Sales to customers	$ 775	1,325	$ 1,928	2,739
Percent Change (as a percent)	(41.50%)		(29.60%)
MEDICAL DEVICES | Surgery | GENERAL | U.S.
Sales by segment of business
Sales to customers	$ 213	530	$ 676	1,127
Percent Change (as a percent)	(59.80%)		(40.00%)
MEDICAL DEVICES | Surgery | GENERAL | International
Sales by segment of business
Sales to customers	$ 562	794	$ 1,252	1,612
Percent Change (as a percent)	(29.20%)		(22.40%)
MEDICAL DEVICES | Vision
Sales by segment of business
Sales to customers	$ 695	1,161	$ 1,762	2,290
Percent Change (as a percent)	(40.10%)		(23.00%)
MEDICAL DEVICES | Vision | U.S.
Sales by segment of business
Sales to customers	$ 248	461	$ 687	907
Percent Change (as a percent)	(46.10%)		(24.20%)
MEDICAL DEVICES | Vision | International
Sales by segment of business
Sales to customers	$ 447	701	$ 1,075	1,383
Percent Change (as a percent)	(36.10%)		(22.30%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 554	842	$ 1,368	1,666
Percent Change (as a percent)	(34.10%)		(17.90%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales to customers	$ 203	333	$ 549	654
Percent Change (as a percent)	(39.00%)		(16.10%)
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales to customers	$ 352	509	$ 819	1,011
Percent Change (as a percent)	(30.90%)		(19.00%)
MEDICAL DEVICES | Vision | SURGICAL
Sales by segment of business
Sales to customers	$ 141	319	$ 394	624
Percent Change (as a percent)	(55.80%)		(36.80%)
MEDICAL DEVICES | Vision | SURGICAL | U.S.
Sales by segment of business
Sales to customers	$ 45	128	$ 138	253
Percent Change (as a percent)	(64.60%)		(45.30%)
MEDICAL DEVICES | Vision | SURGICAL | International
Sales by segment of business
Sales to customers	$ 96	$ 191	$ 256	$ 371
Percent Change (as a percent)	(49.90%)		(31.00%)

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	Apr. 01, 2019	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		(10.80%)		(3.80%)
Sales to customers		$ 18,336	$ 20,562	$ 39,027	$ 40,583
Percentage Change in Operating Income Loss		(44.00%)		(8.80%)
Earnings before provision for taxes on income		$ 3,940	7,041	$ 10,449	11,463
In-process research and development		6	0	6	890
Reversal of contingent consideration				983	0
Restructuring charges		61	57	119	93
Consumer Health*
Segment Reporting Information [Line Items]
Sales to customers		3,296	3,544	6,921	6,862
Litigation expense		600	200	600	200
PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers		10,752	10,529	21,886	20,773
In-process research and development					900
Litigation expense					400
Research and Development Expense					300
Medical Devices
Segment Reporting Information [Line Items]
Sales to customers		4,288	6,489	10,220	12,948
Restructuring charges		100	100	200	200
Litigation expense			200		300
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 4,192	7,272	$ 10,821	11,841
Percentage Change in Operating Income Loss		(42.40%)		(8.60%)
Operating Segments | Consumer Health*
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 32	406	$ 802	1,147
Percentage Change in Operating Income Loss		(92.10%)		(30.10%)
Amortization		$ 100	100	$ 200	200
Operating Segments | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 4,514	3,677	$ 8,348	6,008
Percentage Change in Operating Income Loss		22.80%		38.90%
Amortization		$ 800	800	$ 1,600	1,600
Unrealized Gain (Loss) on Securities		500	200	200	300
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income		(354)	3,189	$ 1,671	4,686
Percentage Change in Operating Income Loss				(64.30%)
Amortization		200	200	$ 500	500
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 252	231	372	378
Ci:z Holdings Co. Ltd. | Consumer Health*
Segment Reporting Information [Line Items]
Gain on sale of equity investments			300
Auris Health
Segment Reporting Information [Line Items]
Reversal of contingent consideration				$ 983
United States
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		(8.30%)		(1.40%)
Sales to customers		$ 9,539	10,403	$ 20,238	20,532
United States | Consumer Health*
Segment Reporting Information [Line Items]
Sales to customers		1,557	1,537	3,297	2,975
United States | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers		6,120	5,783	12,181	11,365
United States | Medical Devices
Segment Reporting Information [Line Items]
Sales to customers		$ 1,862	3,083	$ 4,760	6,192
Europe
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		(14.20%)		(4.80%)
Sales to customers		$ 4,063	4,733	$ 8,890	9,342
Western Hemisphere, excluding U.S.
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		(22.10%)		(10.90%)
Sales to customers		$ 1,133	1,455	$ 2,635	2,958
Asia-Pacific, Africa
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area		(9.30%)		(6.30%)
Sales to customers		$ 3,601	3,971	$ 7,264	7,751
AdvancedSterilizationProducts
Segment Reporting Information [Line Items]
Gain from divestiture of business	$ 2,000
AdvancedSterilizationProducts | Medical Devices
Segment Reporting Information [Line Items]
Gain from divestiture of business			$ 2,000		$ 2,000
Other Income | Auris Health
Segment Reporting Information [Line Items]
Reversal of contingent consideration		$ 1,000
Other Income | Auris Health | Medical Devices
Segment Reporting Information [Line Items]
Reversal of contingent consideration				$ 1,000

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Sales by geographic area
Sales	$ 18,336	$ 20,562	$ 39,027	$ 40,583
Percentage Change In Sales By Geographic Area	(10.80%)		(3.80%)
United States
Sales by geographic area
Sales	$ 9,539	10,403	$ 20,238	20,532
Percentage Change In Sales By Geographic Area	(8.30%)		(1.40%)
Europe
Sales by geographic area
Sales	$ 4,063	4,733	$ 8,890	9,342
Percentage Change In Sales By Geographic Area	(14.20%)		(4.80%)
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,133	1,455	$ 2,635	2,958
Percentage Change In Sales By Geographic Area	(22.10%)		(10.90%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,601	$ 3,971	$ 7,264	$ 7,751
Percentage Change In Sales By Geographic Area	(9.30%)		(6.30%)

Business Combinations and Div_2

Business Combinations and Divestitures - Narrative (Details) SFr / shares in Units, shares in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Jul. 09, 2020USD ($)shares	Jul. 09, 2020CHF (SFr)SFr / sharesshares	Apr. 01, 2019USD ($)	Jan. 17, 2019USD ($)	Jan. 17, 2019JPY (¥)	Jun. 28, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 28, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 28, 2020CHF (SFr)	Dec. 29, 2019USD ($)	Jan. 16, 2019
Business Acquisition [Line Items]
Payments to acquire businesses								$ 949	$ 5,346
Goodwill						$ 33,890		33,890			$ 33,639
Contingent consideration						796		796			$ 1,715
Reversal of contingent consideration								983	0
Other (income) expense, net						(24)	$ 1,683	655	$ 1,705
bermekimab
Business Acquisition [Line Items]
Payments to acquire businesses						800
Intangible assets						800		800
Verb Surgical Inc.
Business Acquisition [Line Items]
Intangible assets						400		400
Goodwill						200		200
Other assets						200		200
Liabilities assumed						300		300
Fair value of previously held equity investment						400		400
Auris Health
Business Acquisition [Line Items]
Payments to acquire businesses			$ 3,400
Intangible assets			3,000
Goodwill			2,000
Liabilities assumed			1,800
Contingent consideration			2,350			200		200
Marketable securities			200
Reversal of contingent consideration								983
Ci:z Holdings Co. Ltd.
Business Acquisition [Line Items]
Intangible assets						1,500		1,500
Goodwill						1,200		1,200
Liabilities assumed						400		400
Business acquisition cost				$ 2,100	¥ 230
Foreign exchange rate												109.06
Other (income) expense, net							$ 300
Adjustments made to intangible assets						100		$ 100
Weighted average useful life								15 years 3 months 18 days
AdvancedSterilizationProducts
Business Acquisition [Line Items]
Gain from divestiture of business			2,000
Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain
Business Acquisition [Line Items]
Assets held for sale, current						100		$ 100
Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts
Business Acquisition [Line Items]
Disposal group consideration			2,800
Disposal group consideration, cash			2,700
Receivables retained			$ 100
Idorsia | Subsequent Event
Business Acquisition [Line Items]
Shares issued in transaction (in shares) | shares	11.8	11.8
Percentage ownership before transaction	8.30%	8.30%
Gross proceeds on sale	$ 357	SFr 337
Sales price per share (in CHF per share) | SFr / shares		SFr 28.55
Ownership interest after sale | shares	38.7	38.7
Percentage ownership after transaction	20.00%	20.00%
Idorsia | Convertible Debt | Idorsia
Business Acquisition [Line Items]
Long-term Debt | SFr										SFr 445
Idorsia | Idorsia | Line of Credit | Revolving Credit Facility
Business Acquisition [Line Items]
Line of credit | SFr										SFr 243
Other Income | Auris Health
Business Acquisition [Line Items]
Reversal of contingent consideration						$ 1,000

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	1 Months Ended			3 Months Ended	6 Months Ended
	Jun. 28, 2020USD ($)claimantpatient	Jan. 31, 2020USD ($)	Jul. 31, 2018USD ($)	Dec. 29, 2019USD ($)claimant	Jun. 28, 2020USD ($)claimantpatient	Oct. 31, 2019USD ($)
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	800				800
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	8,600				8,600
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	15,600				15,600
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	10,600				10,600
XARELTO®
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	21,000				21,000
Talc
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	20,600				20,600
Invokana
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	300				300
Physiomesh
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants	3,700				3,700
Opioid
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants				2,900
Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded | $		$ 6.8		$ 8,000	$ 344
Pending Litigation
Legal Proceeding (Textuals)
Loss Contingency, Estimate of Possible Loss | $						$ 4,000
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement | patient	10,000				10,000
Baby Powder
Legal Proceeding (Textuals)
Previous damages awarded and revised | $			$ 4,700
Baby Powder | Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded | $	$ 2,100
Oklahoma Attorney General vs. Johnson & Johnson and JPI | settled litigation
Legal Proceeding (Textuals)
Damages awarded | $					$ 465
Oklahoma Attorney General vs. Johnson & Johnson and JPI | Judicial Ruling
Legal Proceeding (Textuals)
Damages awarded | $					$ 572

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 61	$ 57	$ 119	$ 93
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	115		233
Restructuring charges recorded to date	1,100		1,100
Supply Chain | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges	61		119
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	22		37
Supply Chain | Other (income) expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	32		77
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	1,900		1,900
Cost savings expected	600		600
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	2,300		2,300
Cost savings expected	800		800
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges			233
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 100	$ 100	$ 200	$ 200
Medical Devices | Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Period for activity			4 years
Medical Devices | Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Period for activity			5 years

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 61	$ 57	$ 119	$ 93
Period of cash outlays for severance expected to be paid out			2 years
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning			$ 180
Restructuring charges			233
Payments for Restructuring			(209)
Restructuring Reserve, Settled without Cash			(44)
Reserve balance ending	160		160
Medical Devices | Employee Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning			164
Restructuring charges			0
Payments for Restructuring			(12)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	152		152
Medical Devices | Asset Write-off
Restructuring Reserve [Roll Forward]
Reserve balance beginning			0
Restructuring charges			27
Payments for Restructuring			0
Restructuring Reserve, Settled without Cash			(27)
Reserve balance ending	0		0
Medical Devices | Other Restructuring
Restructuring Reserve [Roll Forward]
Reserve balance beginning			16
Restructuring charges			206
Payments for Restructuring			(197)
Restructuring Reserve, Settled without Cash			(17)
Reserve balance ending	$ 8		$ 8